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Glucocorticoid excess as a result of Cushing’s syndrome or pharmacological 
treatment can result in the development of obesity and type 2 diabetes mellitus 
(T2DM).  The reactivation of cortisone to cortisol is catalysed by 11βHSD1 which is 
expressed widely but notably in adipose tissue and liver. Studies have shown 
dysregulation of cortisol in these tissues with obesity potentially promoting the 
development of T2DM. Inhibition of 11βHSD1 has been attempted as a novel 
treatment for T2DM with observed improvement in glycaemic control, body weight 
and blood pressure. The efficacy of such agents has been disappointing with few 
reaching phase 2 trials. With recent evidence of bidirectional activity of 11βHSD1 in 
vivo it becomes apparent that dysregulation may occur at an intracellular rather than 
tissue level.   
In this thesis I address several key outstanding questions concerning the physiology 
and regulation of 11βHSD1 including: 
1. Whether combined therapy with metformin alters 11βHSD1 activity and 
obscures the efficacy of  11βHSD1inhibitors;  
2. Whether the contribution of 11βHSD1 to local cortisol concentrations has 
been under-estimated by considering total rather than free cortisol turnover; 
and 
 
3. Whether recycling between cortisol and cortisone in adipose tissue and 
skeletal muscle in obesity is a neglected feature of 11βHSD1 biochemistry 
and function.   
Eight obese healthy men with and without type 2 diabetes were recruited to a 
randomised placebo controlled cross over trial. They received 4 weeks treatment 
with metformin and placebo. Participants with T2DM additionally received 
gliclazide as a further control. Using the deuterated tracer D4-cortisol 11βHSD1 
activity was measured. Metformin treatment increased whole body 11βHSD1 in both 
groups postulated as a result of improved insulin sensitivity.  
11βHSD1 is located within cells and so contributes to free tissue cortisol 
concentrations but perhaps less so to total (protein-bound) cortisol in plasma. It has 
been shown that 11βHSD1 contributes almost half of total circulating cortisol 
concentrations at rest. This measurement relied upon blood sampling during steady 
state deuterated cortisol (D4-cortisol) infusion with measurements of total (free plus 
protein bound) cortisol which may have underestimated true 11βHSD1 activity. This 
was therefore investigated by comparing 11βHSD1 activity as calculated using total 
compared with free cortisol tracer enrichments. Equilibrium dialysis was performed 
separating free from bound portions in plasma samples taken from healthy volunteers 
who received D4-cortisol infusion. Analysis revealed similar measurements of 
11βHSD1 activity using free compared with total cortisol implicating rapid turnover 
of glucocorticoids between the free and bound pools.    
On first discovery 11βHSD1 was seen to be a dehydrogenase enzyme in vitro. Later 
work recognised reductase activity in vivo and up until recently 11βHSD1 has been 
 
viewed as a predominantly reductase enzyme. As with other enzymes in the same 
family, the ability to catalyse both reductase and dehydrogenase depends upon the 
availability of substrate and co substrate. Whether dysregulation of 11βHSD1 in the 
settings of obesity and T2DM is the result of alteration in directionality at a cellular 
level is not known. Firstly bidirectional activity of 11βHSD1 was confirmed in vitro 
using HEK-293 cells stably transfected with 11βHSD1. The influence of obesity and 
acute perturbation with hyperinsulinaemia was subsequently investigated in vivo in a 
random order cross over single blinded case control study involving ten normal 
weight and ten obese healthy male volunteers. D4-cortisol and deuterated cortisone 
(D2-cortisone) were infused for the measurement of reductase and dehydrogenase 
activity of 11βHSD1 respectively with measurements taken across forearm muscle 
and abdominal subcutaneous adipose tissue. Across whole body, lean and obese 
individuals displayed similar 11β-reductase and 11β-dehydrogenase activity. Across 
tissue, 11β-reductase and 11β-dehydrogenase activity was different from zero across 
adipose tissue in obese individuals and across skeletal muscle in lean individuals 
providing further evidence of tissue specific differences in 11βHSD1 with obesity. 
With the addition of hyperinsulinaemia, reductase and dehydrogenase activity was 
somewhat increased in lean individuals although there was no statistically significant 
difference between lean and obese individuals. Across tissue there was a trend for 
obese individuals to display increased 11β-reductase activity across adipose tissue 
with hyperinsulinaemia. Comparing the rates of reductase and dehydrogenase 
activity revealed predominantly reductase activity across tissue in obese and 
dehydrogenase activity in lean individuals. The development of direction specific 
 
inhibitors targeting reductase activity by 11βHSD1 may prove efficacious for the 
treatment of obesity.      
In conclusion, 11βHSD1 acts as a bidirectional enzyme in vitro and in vivo. Overall 
directionality of enzyme activity is altered in a tissue specific manner in the setting 
of obesity. We have shown that this intracellular regulation of cortisol is reflected 
equally in the metabolically active free pool and total plasma pool. The efficacy of 
11βHSD1 inhibitors as novel agents for the treatment of T2DM and coexisting 
obesity is not diminished by co-prescription with metformin but may prove more 
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1.1 Cortisol function 
Glucocorticoids regulate metabolic, cardiovascular and immune parameters allowing 
adaptive changes to be made in response to an altering environment with the aim of 
maintaining whole body homeostasis. Such adjustments include mobilisation or 
storage of energy and modulation of immune response and cardiovascular 
parameters. Acute elevation in circulating cortisol occurs physiologically (such as 
morning wakening and eating) and during pathological stress (such as infection) and 
psychological stress. Chronic stimulation of this mechanism can be detrimental, 
coined allostatic load (McEwen 1998). The detrimental effects of excess circulating 
cortisol are easily seen with exogenous glucocorticoid administration (Wei, et al. 
2004) and autonomous cortisol generation in spontaneous Cushing’s syndrome 
(Giordano, et al. 2011). Such individuals develop central adiposity, hypertension 
dyslipidaemia and altered glucose regulation. Such features are additionally 
encountered in the increasingly prevalent metabolic syndrome. Contrary to 
expectation cortisol concentrations have consistently been found to be lower in 
obesity (Rask, et al. 2001; Rask, et al. 2002). Excretion rates of cortisol and its 
metabolites in urine are concomitantly elevated (Marin, et al. 1992; Strain, et al. 
1982; Strain, et al. 1980) implicating dysregulation of cortisol with obesity in a tissue 
specific manner (Rask et al. 2001; Rask et al. 2002). 
Clear evidence exists of a relationship between elevated circulating cortisol and the 
development of cardiovascular disease (Etxabe and Vazquez 1994; Wei et al. 2004). 
More subtle changes in circulating cortisol, such as higher morning cortisol 
concentrations, have been associated with cardiovascular risk factors including 
hypertension (Bjorntorp, et al. 1999; Litchfield, et al. 1998; Whitworth, et al. 1995), 
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dyslipidaemia (Walker, et al. 2000) and altered glucose regulation (Bjorntorp et al. 
1999). An association of such diurnal variations in cortisol concentrations with hard 
endpoint cardiovascular disease is harder to elicit (Alevizaki, et al. 2007; Reynolds, 
et al. 2009).  
This thesis concentrates on the role of cortisol in regulating metabolic activity in 
adipose tissue, skeletal muscle and liver, and the modulation of cortisol action by 
local activity of the enzyme 11 β-hydroxysteroid dehydrogenase type 1. 
 
1.2 Cortisol structure 
Glucocorticoids are a sub-family of steroid hormones; all steroid hormones have the 
same basic structure consisting of three cyclohexane rings and one cyclopentane 
ring. The addition of side chain moieties around this structure results in the hormone 
specific function. Each ring is labelled A to D with sequential numbering of the 
carbon atoms around each ring in turn allowing identification and standardised 
naming of each compound (Figure 1.1). Cortisol is defined structurally by its 
hydroxyl group at position 11. This contrasts with the inactive form of the 
glucocorticoid, cortisone which differs only by the loss of two hydrogen atoms 
generating a carbonyl functional group allowing easy conversion between the two. 
Dehydrogenation of cortisol generating cortisone occurs by the action of the 11β-
hydroxysteroid dehydrogenase enzymes, namely type 1 (11βHSD1) and type 2 
(11βHSD2). The function of 11βHSD1 will be discussed in detail in the relevant 
sections below.  
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Figure 1.1 Generic structure of steroid compounds 
 
1.3 Cortisol production  
1.3.1 Central regulation 
Cortisol is synthesised via a multi-step enzymatic reaction in the zona fasciculata, the 
middle layer, of the adrenal gland. This process is initiated and controlled through 
the hypothalamic-pituitary-adrenal axis (HPA axis). Through a negative feedback 
loop fine control of circulating glucocorticoids can be achieved.   
The hypothalamus receives afferent signals from neuroendocrine pathways, 
inflammatory mediators and from the limbic system controlling the secretion of 
corticotropin-releasing hormone (CRH). Potentiating the effect of CRH is 
vasopressin (AVP) which is co-secreted by the parvocellular neurons of the 
hypothalamic paraventricular nucleus. Inflammatory cytokines, serotonin and 
acetylcholine have a positive stimulating effect on the hypothalamus whereas 
substance P, gamma-aminobutyric acid-benzodiazepine (GABA-BDZ) and opioid 
peptides have an inhibitory effect on CRH release.  
Neuronal stimulation of the hypothalamus releases CRH into the portal vessel system 
activating the synthesis of the pro-hormone pro-opiomelanocortin (POMC) by the 
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anterior pituitary. This is cleaved producing several peptides including 
adrenocorticotropic hormone (ACTH). Through G-protein coupled receptor, ACTH 
initiates steroidogenesis within the adrenal cortex.  
A rapid ‘fight and flight’ response to stress is stimulated by CRH and AVP through 
corticotropin releasing hormone receptor 1 (CRHR1) initiating behavioural, 
neuroendocrine and autonomic response to stress.  
In the short term the activation of the HPA axis to psychological or environmental 
stress aims to restore homeostasis. Regulation of  whole body cortisol concentrations 
by this feedback mechanism has been seen to be disrupted with obesity (Mattsson, et 
al. 2009) and glucose intolerance (Reynolds, et al. 2001b) and may potentiate the 
development of cardiovascular disease (Reynolds et al. 2001b).   
Per Bjorntorp first identified the potential association between altered cortisol 
regulation through the HPA axis and the development of features of the metabolic 
syndrome and with it an increased risk of cardiovascular disease (Björntorp 1988). 
This was later corroborated in men of low birth weight who were observed to have 
altered HPA axis function and increased development of the metabolic syndrome 
(Reynolds, et al. 2001a). Obese individuals have been observed to have heightened 
response of pituitary control both to stimulation, by CRH (Rask et al. 2002), and 
suppression, by dexamethasone (Rask et al. 2001). A study by Mattsson et al. 
revealed both the synergistic effect of glucocorticoid and mineralcorticoid receptor 
activation on HPA axis negative feedback as well as reduced responsiveness of this 
feedback in obese individuals (Mattsson et al. 2009).  
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This evidence provides the basis for the development of 11βHSD1 inhibitors for the 
treatment of components of the metabolic syndrome and as such with potential to 
reduce the risk of future development of cardiovascular disease. 
 
 
Figure 1.2 Central regulation of cortisol production through the hypothalamic-pituitary adrenal 
axis 
5-HT; serotonin: Ach; acetylcholine: GABA;gamm-aminobutyric acid  :AVP; vasopressin: 
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1.3.2 Adrenal steroidogenesis 
ACTH initiates steroidogensis by binding to melanocortin-2 receptor (MC2R) in the 
adrenal cortex. The initial and rate limiting step in steroid production is the 
incorporation of the starting material, cholesterol, into the mitochondria. This is 
hydrolysed by CYP11A1 generating pregnenolone. The hydroxyl group at carbon 
position 3 is subsequently oxidised by 3β-hydroxysteroid dehydroengase type 2 
forming progesterone. Pregnenolone and progesterone can follow one of three 
pathways, depending on the location within the adrenal gland and as such the 
availability of specific enzymes resulting in the formation of (a) the 
mineralococorticoid aldosterone, primarily from the outer zona glomerulosa, 
(b) cortisol from the middle zona fasciculate and (c) androgens from the innermost 
zona reticularis. The production of cortisol necessitates the presence of 17α-
hydroxylase for the generation of 17 hydroxy-pregenolone or 17 hydroxy-
progesterone from pregenelone and progesterone respectively. From here enzymatic 
reactions involve 21 hydroxylase and 11β-hydroxylase resulting in the end product 
cortisol. Failure of one of these pathways, through enzyme deficiency or 
malfunction, can result in an accumulation of ‘upstream’ intermediate compounds 





















Figure 1.3 Adrenal steroidogenesis pathway 
 
As cortisol is secreted on demand, acute adjustments can be made to bio-available 
steroid. Both the hypothalamus and pituitary glands detect circulating cortisol levels 
with inhibition of CRH and ACTH production when adequate levels are sensed in a 
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1.3.3 Cortisol secretion  
 Cortisol secretion follows a natural circadian rhythm with elevated concentrations 
upon wakening reducing to a nocturnal nadir. Smaller fluctuations additionally occur 
throughout the day in an ultradian rhythm in relation to eating and in response to 
stress and alterations in the external environment. Such sensitive manipulations are 
feasible through adjustments in the pulsatile nature in which ACTH is secreted. 
Elevated morning concentrations is primarily as a result of increased amplitude 
(Veldhuis, et al. 1990) whereas nocturnal nadir is through a reduction in the 
frequency of these pulses (Horrocks, et al. 1990). 
 
1.4 Corticosteroid Binding Globulin 
Over 90% of cortisol circulates bound to the carrier protein corticosteroid binding 
globulin (CBG). A small proportion is additionally bound to albumin leaving less 
than 5% to circulate free. It is this unbound portion which diffuses into the 
extravascular compartment and is metabolically active. Binding and dissociation of 
cortisol to CBG is a dynamic process and can therefore be seen as an additional level 
of regulation in the control of cellular cortisol action. Binding affinity of cortisol to 
CBG is altered with fluctuations in temperature (Cameron, et al. 2010) and pH 
(Mickelson, et al. 1981) with high temperatures and acidic conditions instigating 
cortisol dissociation. Cortisone competes with cortisol for the binding site on CBG 
but with an affinity 10 times less than cortisol (Dunn, et al. 1981).   
1.4.1 CBG as a carrier protein  
CBG is a member of the serine protease inhibitors (serpin) family although it lacks 
any inhibitory action on protease enzymes. Like other members of the serpin family 
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it undergoes dramatic conformational change from stressed to relaxed state. In the 
stressed state the cortisol binding pocket, or reactive centre loop (RCL), is exposed 
whereas in the relaxed state it is concealed by the main β sheet of the protein (Figure 
1.4). This conformational change, catalysed by cleavage of the RCL by neutrophil 
elastase, results in around a nine fold reduction in binding affinity (Chan, et al. 2013; 
Hammond, et al. 1990). It is hypothesised that this allows greater dissociation of 
cortisol at sites of inflammation although studies have only proven this in vitro 
(Hammond et al. 1990). Antibodies directed at the exposed reactive centre loop in 
stressed CBG molecules have been developed. Paired measurement of total CBG 
concentrations then allows quantification of conformational change in a variety of 
situations (Lewis and Elder 2011). Through their use one study has shown a direct 
relationship between sepsis of increasing severity and circulating levels of cleaved 
low affinity CBG (Nenke, et al. 2015). Shock secondary to sepsis resulted in greater 
cleavage of CBG compared to shock of other cause (such as cardiogenic) despite 
non-significantly different total white cell count implicating differential white cell 
count, for example neutrophils, in mediating this conformational change.      
 
 
      
 
Figure 1.4 Schematic of cleavage of corticosteroid binding globulin (CBG) from stressed to 
relaxed state  
Cleavage of reactive centre loop (RCL) by 
proteinases 
CBG molecule in 
stressed state 
High affinity 
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Unlike albumin, CBG has a high affinity for cortisol but low binding capacity with 
saturation occurring at cortisol concentrations of around 500 nM. With cortisol 
circulating at around this concentration throughout most of the circadian curve, an 
exponential rise in free cortisol is precipitated with any additional cortisol 
production.  
1.4.2 Alteration in CBG binding affinity and capacity  
CBG binding capacity is influenced by other circulating hormone levels including 
insulin, oestrogens and glucocorticoids. Stimulated insulin secretion through the use 
of an intravenous glucose infusion results in an acute reduction in CBG 
concentrations postulated to be the result of reduced hepatic synthesis (Fernandez-
Real, et al. 2001). This effect is lost in the presence of insulin resistance. Oestrogens 
increase CBG production (Musa, et al. 1965) whilst glucocorticoids have a negative 
feedback role (Schlechte and Hamilton 1987).  
Akin to other circulating peptides, CBG is open to glycosylation.  Six consensus sites 
are available for modification. Glycosylation at amino acid Asn238 is necessary for 
the correct folding and generation of the steroid-binding site during biosynthesis 
(Avvakumov and Hammond 1994). Post-transcription glycosylation plays a 
significant role in altering binding affinity with glycosylated CBG demonstrating a 
nine fold greater affinity for cortisol (Chan et al. 2013). Whether higher circulating 
glucose concentrations such as with diabetes mellitus results in such alterations 
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1.4.3 CBG transcription and mutations 
CBG is encoded from a 19kb gene (SERPINA6) on Chromosome 14. This sits in 
close proximity to the gene encoding α-1 antitrypsin (SERPINA1). Alpha-1 
antitrypsin is a further member of the serpin protease family which inhibits the action 
of neutrophil elastase. The effects of inherited deficiency of α-1 antitrypsin on 
respiratory and gastrointestinal function are well understood but potential effects on 
CBG binding affinity and circulating cortisol concentrations is unknown.   
The first kindred of CBG mutation was identified as a result with a lack of response 
of CBG to increase sufficiently with oestrogen treatment (Doe, et al. 1965). Since 
then a variety of CBG mutations have been identified. The Leuven (Van Baelen, et 
al. 1982) and Lyon (Emptoz-Bonneton, et al. 2000) mutations result from a single 
amino acid substitution resulting in altered coupling mechanism between steroid and 
binding site and a resultant reduction in cortisol binding affinity (Klieber, et al. 
2007). Individuals holding these mutations display symptoms of asthenia, depression 
and occasionally hypertension thought to be the result of relative glucocorticoid 
insufficiency.   
Following presentation with symptoms consistent with hypoadrenalism, inadequate 
response to synthetic ACTH yet normal urinary free cortisol concentrations, the null 
mutation with complete loss of CBG was discovered (Torpy, et al. 2001). This 
results from a base substitution and subsequent premature stop codon preventing 
CBG transcription. Unexplained fatigue and hypotension have variably been reported 
in such individuals. A partial loss of CBG transcription  to  around 50% has 
additionally been observed in a young boy presenting with fatigue and headache 
(Torpy, et al. 2012). It must be clarified that the aforementioned mutations are all 
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rare. A much larger variety of single nucleotide polymorphisms (SNP) do, however, 
exist with variable consequences on production and/or function of CBG (Simard, et 
al. 2015). Symptomatology from these mutations is diverse potentially leading to 
under-diagnosis and the generation of skepticism as to extent of their impact. 
Compounding factors such as the environmental have been suggested to play a role 
(Cizza, et al. 2011). It is debated whether individuals with chronic fatigue syndrome 
have relative glucocorticoid insufficiency and certainly there is evidence of impaired 
HPA axis function in some individuals (Demitrack, et al. 1991). With a 
preponderance for a particular SNP, CBG function may play a role in its 
development although none of the well recognized mutations outlined above have 
been proven in such cases (Gagliardi, et al. 2010).  
Genetic polymorphisms of CBG have been shown to explain a proportion (<1%) of 
the variance in circulating cortisol concentrations between individuals. A recent 
genome wide association meta-analysis (GWAS) explored the effect of single 
nucleotide polymorphisms (SNPs) on morning cortisol concentrations. Genetic 
polymorphisms at a locus on Chromosome 14 spanning both SERPINA6 and 
SERPINA1 correlated significantly (P<5x10-8) with morning cortisol concentrations 
and were observed to influence total binding capacity of CBG as well as influencing 
CBG cleavage (Bolton, et al. 2014).      
 
1.4.4 CBG and the metabolic syndrome 
CBG concentrations have been observed in a large population study to be inversely 
related to indices of obesity including BMI, waist to hip ratio as well as with blood 
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pressure (Fernandez-Real, et al. 2002). As a state of chronic inflammation this may 
be the result of down regulated synthesis. With recognised HPA axis dysfunction  in 
association with obesity (Mattsson et al. 2009), lower CBG levels may help maintain 
adequate cellular glucocorticoid exposure. Certainly, evidence exists for enhanced 
adipose tissue proliferation and differentiation in the presence of lower circulating 
CBG concentrations which is not explained by either GR or 11βHSD1 action 
(Joyner, et al. 2003). This may contribute to an increased prevalence of obesity with 
relative or complete CBG deficiency (Roitman, et al. 1984). 
Association between CBG and other markers of the metabolic syndrome such as 
insulin resistance are less consistent (Fernandez-Real, et al. 1999; Fernández-Real, et 
al. 2000; Lewis, et al. 2004).  
 
1.5 Glucocorticoid receptor and signalling pathway 
Intracellular activation of the glucocorticoid receptor (GR) by glucocorticoids results 
in the initiation of a wide variety of processes aimed at maintaining homeostasis. 
Alternative splicing in the generation of GR provides functionally distinct subtypes 
allowing tissue and regulatory specificity (Lewis-Tuffin and Cidlowski 2006). 
Glucocorticoids bind to the ligand binding domain, a hydrophobic pocket embedded 
within the protein. This dimerised product then translocates to the nucleus where it 
binds with high affinity to target DNA sequences known as Glucocorticoid Response 
Element (GRE). GREs can either positively enhance or down regulate gene 
transcription. The GRE sequence itself influences gene transcription rates through 
the recruitment of coregulators and chromatin remodelling complexes (Rosenfeld 
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and Glass 2001). Proinflammatory transcription factors such as activator protein-1 
and NF-κB tether to GR or co-localise to GRE down regulating transcriptional 
activity. This is one means by which glucocorticoids exert their anti-inflammatory 
and immunosuppressive effect (Newton and Holden 2007). Upregulation of gene 
transcription is promoted by proteins such as STAT (signal transducer and activator 
of transcription) molecules which act synergistically with GR (Rogatsky and 
Ivashkiv 2006).  
Glucocorticoid receptors are open to post translational modification through the 
action of mitogen activated protein kinase (MAPK), cyclin dependent kinases and 
glycogen synthase kinase-3 (Oakley and Cidlowski 2011). The best studied 
modification is phosphorylation (Beck, et al. 2009) which not only modifies gene 
transcription (Miller, et al. 2005) but may influence the half life and stability of the 
protein (Webster, et al. 1997). The MAPK signalling pathway regulates the 
generation of pro-inflammatory proteins. By inhibiting this pathway, glucocorticoids 
regulate cellular inflammation. In turn MAPK has the ability to negatively feedback 
through post translational modification of GR (Ayroldi, et al. 2012).  
In contrast to transcriptional effects of GR which take a few hours to initiate, non 
genomic effects such as blockage of neuronal signals through high-voltage-gated-
calcium channels and inhibition of inflammatory cascade through inhibition of 
arachidonic release occurs within minutes (Song and Buttgereit 2006; Tasker, et al. 
2006). 
As ligands, glucocorticoids are not exclusive to GR but bind to mineralocorticoid 
receptors (MR) with equivalent, if not higher binding affinity than the 
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mineralcorticoiod, aldosterone (Funder 2005). The lower abundance of MR 
compared with GR and the role of glucocorticoid inactivating enzymes such as 
11βHSD2 help prevent inappropriate activation of MR by cortisol.   
Glucocorticoid receptors are widely distributed and diverse with as much as 20% of 
the human genome being regulated by glucocorticoids (Galon, et al. 2002). 
Interaction of GR with GRE occurs in pulses rapidly cycling on and off every few 
seconds allowing optimal gene targeting. In contrast, activation of MR persists over 
longer periods and between pulses (de Kloet, et al. 2005). Considerable 
heterogeneity exists in sensitivity of GR to their ligand between individuals (Cain 
and Cidlowski 2015) which may predict susceptibility to detrimental consequences 
of dysregulated circulating cortisol (Walker, et al. 1996).  
The location and function of MR has long been thought to primarily be renal control 
of salt regulation and blood pressure control (Funder 2005). This has been challenged 
with more widespread identification of MR in non–epithelial tissue such as adipose. 
With the observation that activation of MR promotes differentiation of fibroblasts 
into mature adipocytes (Caprio, et al. 2007; Rondinone, et al. 1993), questions are 
raised as to whether the detrimental effects of glucorticoids on the development of 
obesity and features of the metabolic syndrome are in fact through stimulation of GR 
or MR. Certainly adipogenesis of human preadipocytes can be inhibited by MR 
antagonism (Caprio, et al. 2011) and glucose dysregulation in mice fed on a high fat 
diet can be ameliorated with spironolactone treatment, a selective MR antagonist 
(Wada, et al. 2010). The mechanism of action is postulated to be through down-
regulated transcription of proinflammatroy cytokines such as TNF-α and up-
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regulation of adiponectin and peroxisome proliferator-activated receptor-γ (PPAR- γ) 
(Guo, et al. 2008; Hirata, et al. 2009).    
 
1.6 Cortisol metabolism 
With recognition that the hydroxyl form of the glucocorticoid is required for 
biological activity, the enzyme involved in converting cortisone to cortisol in 
peripheral tissues was identified as 11β-hydroxysteroid dehydrogenase. High levels 
of activity were initially observed both in liver and kidney (Burton 1965). 
Purification 20 years later revealed bidirectional activity (Lakshmi and Monder 
1985a) and it wasn’t until characterisation of the isozyme in placenta, now 
recognised as 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) (Brown, et al. 
1993), that two distinct forms of the enzyme were recognised.  
Cortisol and cortisone are metabolised by the 5β-reductase enzymes, found primarily 
in the liver, generating dihydro- forms namely dihydrocortisol and dihydrocortisone. 
Only cortisol is metabolised by the 5α-reductase enzyme (type 1) producing allo-
dihydrocortisol. Further reduction proceeds through the 3α-hydroxysteroid 
dehydrogenases generating the corresponding tetrahydro- metabolites 
(tetrahydrocortisol (THF), allo-tetrahydrocortisol (aTHF) and tetrahydrocortisone 
(THE)) which account for the majority of metabolic clearance of cortisol in humans. 
Measurement of these metabolites in urine and calculation of tetrahydrocortisol to 
tetrahydrocortisone ratios (THF:THE and aTHF:THE) provides assessment of whole 
body 11βHSD1 and 2 activities. Such measurements are impacted by alterations in 
the 5α- and β-reductase enzymes (Palermo, et al. 1996). Studies have shown 
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conflicting effects of obesity on cortisol metabolism with increased 5-α reductase 
activity observed in a study of obese men (Stewart, et al. 1999) yet increased 5-β 
reductase activity in a study involving obese men and post-menopausal women 
(Andrew, et al. 1998).   
Metabolism of cortisol by 11βHSD2 generates inactive cortisone. This process is 
vital to prevent inappropriate activation of MR in epithelial tissues reliant upon 
tightly controlled electrolyte reabsorption such as renal cortex and medulla, salivary 
gland, colonic epithelial cells and sigmoid and rectal colon. The placenta additionally 
contains 11βHSD2 preventing excess exposure of the developing fetus to excess 
glucocorticoids. 
 
1.7 11βHSD1 biology 
In accordance with its structure, 11βHSD is a member of the short chain alcohol 
dehydrogenase/ reducatase (SDR) family made up of 292 amino acids in humans. 
The hydrophobic N terminus binds to the inner endoplasmic reticulum whilst the 
catalytic active site within the lumen allows binding of substrate and co-substrate for 
proton transfer. Co-localised within the endoplasmic reticulum is hexose-6-
phosphate dehydrogenase (H6PDH) which provides the co-substrates NADPH and 
NADP+ in return for the oxidation of glucose-6-phosphate (G6P) to 6-
phosphogluconate (Lavery, et al. 2006). Cortisone has a ten-fold greater affinity for 
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1.7.1 11βHSD1 Directionality  
Hydroxysteroid dehydrogenase enzymes in general terms are involved in the 
interconversion between intermediate and end product steroids as per the steroid 
pathway (Figure 1.3) requiring nicotinamide containing co-substrates for hydride 
transfer. Such reactions are theoretically reversible but directionality is dependent 
upon several factors including pH, structural conformation of the enzyme and 
cofactor concentration. With gross alterations in these an enzyme may appear to act 
in a unidirectional manner (Mizrachi and Auchus 2009). The more 
thermodynamically stable reactions involving the reduction of a ketone to hydroxyl 
additionally promote unidirectionality.   
Purified enzyme from tissue homogenate initially revealed 11βHSD1 as a 
bidirectional enzyme (Lakshmi and Monder 1985b). Work with intact cells 
challenged this with cortisone displaying much greater affinity for the enzyme than 
cortisol (Low, et al. 1994). Since then 11βHSD1 has been regarded as a principally 
reductase enzyme in vivo. There are several reasons why this may not hold true.  
In intact cells, a high NADPH to NADP+ ratio promotes oxo-reductase enzymes to 
catalyse reductase reactions (De Sousa Peixoto, et al. 2008). In the situation of 
11βHSD1, this ratio is influenced by the function of H6PDH since NADPH is unable 
to permeate into the endoplasmic reticulum (Chapman, et al. 2013). Loss of H6PDH 
function as a result of genetic mutations (Lavery, et al. 2008) or reduced availability 
within immature stromal cells (Bujalska, et al. 2002) results in lack of reductase 
activity. Whether tissue specific alteration in enzymatic action seen in relation to 
obesity and T2DM reflects disruption of coenzyme or cosubstrate supply is 
unknown.  
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Other SDR enzymes such as 17-hydroxydehydrogenase enzymes, which interconvert 
weak and potent sex steroids, function in a bidirectional manner (Khan, et al. 2004). 
Directionality of these enzymes is similarly dependent upon whether the cell is intact 
or homogenised, and availability of co-substrate. Activity is additionally altered by 
temperature and pH (Luu-The, et al. 1995). It is of interest when comparing these 
enzymes that those utilising the non phosphorylated coenzyme, NAD, tend to favour 
the oxidative reaction whilst those preferring NADPH, which is in turn more 
abundant, drive in a predominantly reductase direction. Comparatively, 11βHSD1 is 
an NADPH dependent enzyme whilst 11βHSD2 relies upon NAD+.  
1.7.2 11βHSD1 regulation  
Initial studies using purified rat liver enzyme found 11βHSD1 to principally catalyse 
the dehydrogenase reaction (Lakshmi and Monder 1988). Despite the addition of the 
co-substrate NADPH and the presence of cortisone, no reductase activity was 
observed. Further in vitro experiments using a variety of cell types proved that 
activity in the intact cell adopts reductase directionality (Bujalska, et al. 1997; 
Jamieson, et al. 1995; Rajan, et al. 1996). These contrasting observations may 
represent response to alterations in availability of substrate, co-enzyme and as a 
result, co-substrate although this has never been proven. Despite circulating at 
concentrations five to ten times lower than cortisol, the majority of cortisone remains 
unbound from protein which may influence enzyme function in vivo.                
Cytokines such as TNF alpha and IL-1 can upregulate 11βHSD1 activity (Friedberg, 
et al. 2003) and therefore may have a role to play in tissue specific dysregulation of 
11βHSD1 associated with chronic inflammatory conditions such as obesity 
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(Qatanani and Lazar 2007). Circulating growth hormone concentrations can 
additionally alter 11βHSD1 activity but with an inverse relationship (Stewart, et al. 
2001). Gender specific sex steroids increase 11βHSD1 activity whilst leptin has 
varying effects between men and women (Dieudonne, et al. 2006).  
The effects of insulin on 11βHSD1 appear to be variable between individuals and 
tissues.  11βHSD1 activity has been observed to be upregulated in adipocytes treated 
with insulin in vitro in some (Balachandran, et al. 2008) but not all studies 
(Napolitano, et al. 1998). In vivo, acute elevation in circulating insulin using a 
hyperinsulinemic clamp increased whole body and adipose 11βHSD1 activity 
(Wake, et al. 2006). Data from a similar study showed a rapid yet short lived 
reduction in adipose 11βHSD1 activity in lean individuals during acute 
hyperinsulinemia which was not corroborated in obese individuals (Sandeep, et al. 
2005). Mechanistically, insulin results in translocation of glucose transporters to the 
cell membrane increasing the availability of co-substrate for 11βHSD1 activity.  
Hepatocytes cultured with insulin in vitro have been observed to have reduced 
11βHSD1 mRNA but with little effect on overall activity (Jamieson et al. 1995). In 
vivo obese euglycaemic individuals display down regulated hepatic 11βHSD1 
activity (Rask et al. 2001; Rask et al. 2002; Stewart et al. 1999) which is upregulated 
with the addition of relative insulin deficiency as seen with T2DM (Stimson, et al. 
2011). 
A study performed by Stimson et al. showed upregulation of 11βHSD1 activity in 
whole body in response to a high carbohydrate meal (Stimson et al. 2014). The 
magnitude of this response was in proportion to the increase in whole body 
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circulating insulin concentrations providing a potential causation which is backed up 
by findings that acute hyperinsulinaemia enhances 11βHSD1 reductase activity 
(Wake et al. 2006).  
Glucocorticoids themselves have a positive feedback on 11βHSD1 upregulating 
tissue activity resulting in increased cortisol regeneration (Dube, et al. 2015b; 
Morgan, et al. 2014). 
1.7.3 Transcription and modification of 11βHSD1 
The human gene encoding 11βHSD1 (HSD11B1) is located on chromosome 1 (1q32-
41) encompassing 6 exons. The levels of transcripts have been shown to directly 
correlate with enzyme activity (Lindsay et al. 2003; Wake et al. 2003). Post-
translational modification of the protein may alter function and directionality 
although this remains controversial. Agarwal et al. have observed that glycosylation 
of rat 11βHSD1 was necessary for maximal dehydrogenase activity (Agarwal, et al. 
1990). Further work by the same group went on to investigate this further by creating 
loci directed mutagenesis at two individual glycosylation sites. Mutation of one of 
these sites showed a reduction in both dehydrogenase and reductase activity. 
Mutation of both glycosylation sites compounded the effect resulting in negligible 
reductase or dehydrogenase activity  (Agarwal, et al. 1995). Conflicted results have 
been observed using human liver 11βHSD1 where non-glycosylated forms of the 
enzyme retain dehydrogenase and reductase activity (Blum, et al. 2000; Walker, et 
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1.7.4 Genetic variation in human HSD11B1 
The impact of reduced 11βHSD1 reductase activity is observed with the condition of 
Cortisone Reductase Deficiency (CRD). With relatively greater peripheral clearance 
of cortisol, HPA axis stimulation drives increased steroid synthesis which is most 
apparent through elevated androgen concentrations (testosterone, androstenedione 
and dehydroepiandrosterone sulphate (DHEAS)). This presents itself in boys as 
pseudo-puberty whilst in females results in infertitlity, acne and hirsutism. 
Measurement of urinary metabolites in such individuals have revealed a twenty-five 
fold reduction in the ratio of  cortisol: cortisone urinary metabolites (Phillipov, et al. 
1996). Initial association studies failed to correlate HSD11B1 gene polymorphisms 
with identified cases (Jamieson, et al. 1999). With 11βHSD1 function relying on the 
generation of co-substrate, genetic studies moved focus to the coenzyme H6PDH 
revealing mutations in four separate cases (Lavery et al. 2008). More recent work 
has, however, now observed heterozygous mutations in the coding region of 
HSD11B1 returning the concept of direct as opposed to apparent cortisone reductase 
deficiency (Lawson, et al. 2011).      
 
1.8 Measurement of 11βHSD1 activity 
Quantification of urinary cortisol and cortisone metabolites has been used for the 
assessment of disordered whole body 11βHSD activity (Phillipou and Higgins 1985; 
Wilson, et al. 1995). This classically involves calculation of ratio of cortisol (urinary 
free cortisol, THF and allo-THF) to cortisone metabolites (urinary free cortisone and 
THE). This does not allow for distinction between metabolism by the 11βHSD 
enzymes and 5 α-reductase enzyme. Seperation of conjugated (THF, allo-THF and 
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THE) from unconjugated (cortisol and cortisone) metabolites can allow distinction of 
enzyme activity between kidney and liver (Best and Walker 1997) but does not allow 
quantification of activity in alternative tissues such as adipose or muscle and does not 
allow quantification of unidirectional activity of the 11βHSD enzymes (Walker, et al. 
1993).  
With evidence of tissue specific dysregulation of cortisol with obesity (Rask et al. 
2001; Stewart et al. 1999), the need for selective measurement of reductase and 
dehydrogenase activity by 11βHSD in whole body and across tissue becomes 
apparent. Although this may be provided by glucocorticoid quantification in tissue 
biopsies, this is not always practical and does not allow assessment of enzyme 
response to acute perturbations. With a bioavailability of 96%, oral cortisone is 
rapidly converted to its active form through first pass metabolism predominantly 
through the action of the liver (Derendorf, et al. 1991) and more specifically through 
11βHSD1 (Andrew, et al. 2005). By measuring the rate of appearance of cortisol 
following oral cortisone ingestion, reductase activity by hepatic 11βHSD1 can be 
quantified.       
Tracers have been used since the mid 1900s to track metabolic pathways in the body. 
Radioactive compounds were some of the first to be used. Following infusion, 
enzyme activity can be quantified by measuring the difference in radioactivity 
between influx and efflux. More current methods involve the use of isotopes i.e. two 
compounds with the same atomic number but different atomic mass (the number of 
protons and neutrons). Isotopologues occur naturally although at much smaller 
quantities than their parent compound. For use as a tracer these therefore often 
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require synthetic generation based on an endogenous compound, known as the 
tracee. Enzyme activity is calculated by measuring the dilution of one to the other 
referred to as the tracer to tracee ratio. Due to the potential harmful effects of using 
radioactive tracers and the ability to quantify increasingly smaller concentrations of 
endogenous compounds with greater specificity, isotopic tracers are now more 
commonly used. Such tracers have allowed 11βHSD1 activity to be quantified in 
whole body and across tissues including adipose (Stimson, et al. 2009), liver (Basu, 
et al. 2009; Stimson et al. 2011) and skeletal muscle (Basu, et al. 2004). 
1.8.1 11βHSD1 reductase activity  
By replacing four hydrogen atoms with deuterium, the stable isotope of cortisol, 
9,11,12,12-[2H]4–cortisol (D4-cortisol) is produced. In keeping with the definition of 
a tracer, this behaves chemically and physiologically like the endogenous compound. 
It is only the mass difference which allows distinction and quantification. The 
deuterium atom attached to carbon at position 11 is removed by dehydrogenation 
generating 9,12,12-[2H]3-cortisone (D3-cortisone). With the natural abundance of 
deuterium being less than 0.02%, this is an irreversible reaction. Further reduction is 
specific to 11βHSD1 generating 9,12,12-[2H]3-cortisol (D3-cortisol) (Figure 1.5 ). 
The rate of appearance of D3-cortisol on the background of steady influx of D4-
cortisol allows the specific reductase activity of 11βHSD1 to be calculated.  
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Figure 1.5 Schematic showing the use of deuterated tracer D4-cortisol to quantify cortisol to 
cortisone interconversion by 11βHSD1 and 11βHSD2  
 
1.8.2 11βHSD1 dehydrogenase activity 
More recent work within our department has validated the use of a deuterated tracer 
for the measurement of dehydrogenase activity by the 11βHSD enzymes (Hughes, et 
al. 2012). D2-cortisone (1,2-[2H]2-cortisone) (Figure 1.6) is infused to achieve steady 
state and the rate of dilution by endogenous cortisone provides a measure of 
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Figure 1.6 Schematic showing deuterated tracer D2-cortisone used for the measurement of 
dehydrogenase activity by 11βHSD1 and 11βHSD2 
 
1.8.3 Tissue specific measurement of 11βHSD1 activity 
Tracers have allowed quantification of adrenal cortisol synthesis and tissue cortisol 
production rates by 11βHSD1. Cortisol regeneration in splanchnic tissue has been 
found to equate that of the adrenal gland (Andrew et al. 2005) and is almost entirely 
accounted for by the liver (Basu et al. 2009; Stimson et al. 2009).   
The first evidence of tissue specific dysregulation of cortisol in the setting of obesity 
dates back to studies performed by Per Bjorntorp (Marin et al. 1992) who revealed an 
inverse relationship between measures of central obesity and early morning cortisol 
concentrations as a result of higher excretion of cortisol metabolites, mainly in the 
form of cortisone, in urine. Despite lean and obese individuals having similar whole 
body 11βHSD1 activity, obese individuals display upregulated activity in adipose 
tissue (Rask et al. 2001; Sandeep et al. 2005; Stimson et al. 2009). Hepatic 11βHSD1 
activity has been observed to be lower in obese individuals (Rask et al. 2001; Rask et 
al. 2002; Stewart et al. 1999). This counter-balance is disrupted in the setting of 
T2DM where hepatic enzyme activity is sustained (Stimson et al. 2011) hypothesised 
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to be the result of relative insulin deficiency. This latter finding has been challenged 
by another study (Basu, et al. 2005).  
Deuterated cortisol tracers have been used to investigate acute perturbation in 
11βHSD1 activity with evidence that acute elevation in insulin increase whole body 
11βHSD1 in vivo (Stimson, et al. 2014). Across individual tissues, elevated insulin 
and free fatty acid concentrations increases enzyme activity (Wake et al. 2006). This 
effect may not be consistent between lean and obese individuals (Sandeep et al. 
2005).  
 
1.9 Tissue regulation of 11βHSD1  
Distribution of 11βHSD1 is diffuse in metabolically active tissues throughout the 
body. By polymerase chain reaction, 11βHSD1 RNA has been located in the liver, 
lung spleen, cerebellum, pituitary, kidney medulla, and placenta (Whorwood, et al. 
1995).   
1.9.1 Splanchnic tissue  
It was from rat liver tissue that purification and characterization of 11βHSD1 was 
first detailed (Lakshmi and Monder 1985b, 1988) and is now recognized as having 
greatest enzyme expression in both rats and humans (Tannin, et al. 1991). This has 
been corroborated by activity studies which have shown that liver accounts for 
11βHSD1 within splanchnic tissue almost entirely (Basu et al. 2009; Stimson et al. 
2009) and in turn generates cortisol at equivalent rates to that of the adrenal gland 
(Andrew et al. 2005).  Enzyme activity has been observed to be nine fold greater in 
the liver compared with visceral adipose tissue (Basu et al. 2009). The significance 
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of cortisol regeneration by the liver is additionally exemplified in liver specific 
1βHSD1 knockout mice with the development of adrenal hyperplasia in response to 
chronic activation of the HPA axis (Lavery, et al. 2012).  
In mouse models of T2DM, a positive correlation has been observed between 
circulating glucose concentrations and hepatic 11βHSD1 mRNA and activity 
implicating this tissue as a potential driver for development of glucose dysregulation 
associated with obesity (Liu, et al. 2005). Using genetically modified knockout mice 
the mechanism of action has been postulated to be through key gluconeogenic 
enzymes in the liver including glucose-6-phosphatase and phosphoenolpyruvate 
carboxykinase (PEPCK) (Kotelevtsev, et al. 1997). Whole body 11βHSD1 knock-out 
mice have been observed to have more favourable lipid profile (Morton, et al. 2001) 
through altered regulation of lipolytic enzymes (Morton, et al. 2001). The more 
recent development of liver specific knockout mice has, however, failed to 
corroborate such beneficial effects (Lavery et al. 2012) implying potential cross talk 
between target organs or perhaps compensatory mechanisms by the HPA axis (la 
Fleur, et al. 2005).  
Hepatic 11βHSD1 has a further role to play in catalysing the inter-conversion 
between bile acids (Odermatt, et al. 2011) which in turn have an inhibitory effect on 
11βHSD enzyme activity (Diederich, et al. 2000). Their role in altering enzyme 
activity with obesity and T2DM are unknown.  
1.9.2 Adipose tissue  
Some studies have shown the sole presence of 11βHSD1 in ex vivo adipose tissue 
whilst others have additionally observed 11βHSD2 (Bujalska, et al. 1999; Engeli, et 
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al. 2004; Lee, et al. 2008). With distinctly different embryological origins (Chau, et 
al. 2014) it has been debated whether subcutaneous or omental adipose tissue is more 
influential in the development of adverse metabolic outcome. Ex vivo adipose tissue 
samples from men and women undergoing abdominal surgery showed greater 
reductase activity in omental compared with subcutanous tissue (Bujalska et al. 
1997). These results have not been confirmed in a further cohort of women 
(Veilleux, et al. 2010). 11βHSD1 activity in subcutaneous adipose is positively 
correlated with obesity in men (Rask et al. 2001) and women (Rask et al. 2002). 
Increased 11βHSD1 activity in subcutaneous adipose tissue is thought to potentiate 
adverse metabolic consequences to a greater degree than that in omental adipose 
tissue (Alberti, et al. 2007) and positively correlates with fasting plasma glucose, 
plasma insulin concentrations and insulin resistance (Lindsay, et al. 2003). A recent 
study using microdialysis found upregulated 11βHSD1 activity in obese individuals 
with T2DM but not in obese euglycaemic individuals (Dube, et al. 2015a).  
1.9.3 Skeletal muscle  
The effect of glucocorticoids on muscle is well understood with induction of atrophy, 
protein breakdown (Biedasek, et al. 2011; Löfberg, et al. 2002) and impairment of 
insulin induced glucose uptake (Morgan, et al. 2009). Skeletal muscle accounts for 
the major site of glucose disposal and as such is particularly vulnerable to the 
inhibiting effects of cortisol on insulin function (DeFronzo, et al.).  
With a negative correlation between myocyte 11βHSD1 and glucose disposal rate as 
well as a positive correlation with BMI and systolic blood pressure, it is postulated 
that enzyme activity in skeletal muscle may play a significant role in the 
development of the metabolic syndrome (Whorwood, et al. 2002). In agreement, 
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myotubes from obese patients with type 2 diabetes mellitus (T2DM) have been 
shown to have a two fold increase in 11βHSD1 mRNA compared with control 
individuals (Abdallah, et al. 2005). This finding has not been consistent (Jang, et al. 
2007).  
Localisation of 11βHSD2 in skeletal muscle has been conflicting (Abdallah et al. 
2005; Hassan-Smith, et al. 2015; Jang et al. 2007; Whorwood et al. 2002) but may 
rely upon sensitivity of the gene transcription technique used. A recent finding of 
mineralocortcoid receptors in human skeletal muscle (Chadwick, et al. 2015) 
provides a potential physiological need for the presence of 11βHSD2 in this tissue.  
Despite excess abundance of co-enzyme H6PDH for regeneration of co-substrate 
NADPH, 11βHSD1 mRNA is not directly correlated with reductase activity in 
skeletal muscle (Jang, et al. 2006; Jang et al. 2007). Alternative directionality of the 
enzyme or inhibition of enzyme activity as a result of local factors could be potential 
explanations. It has, for instance, been observed in ex vivo muscle biopsies that 
11βHSD1 reductase activity is downregulated in individuals with T2DM (Jang et al. 
2007) thought to be the result of relative insulin deficiency. Incubation with 
dexamethasone reverses this effect returning enzyme activity to that of lean control 
individuals. In contrast, 11βHSD2 activity appears resistant to this effect (Whorwood 
et al. 2002).  Although the contribution of muscle cortisol regeneration is likely to be 
small in comparison to splanchnic tissue, it may confer some protective effect against 
the metabolic sequelae associated with the metabolic syndrome. Indeed, inhibitors of 
11βHSD1 are likely to improve insulin sensitivity in part through their effect on 
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skeletal muscle (Morgan et al. 2009). Few studies have, however, detailed skeletal 
muscle 11βHSD1 activity in humans in vivo.   
 
1.10 Preclinical models of manipulation of 
11βHSD1 
The first evidence of improved metabolic consequences of 11βHSD1 inhibition came 
through whole body 11βHSD1 knock out in genetically modified mice. These 
animals resisted hyperglycaemia despite being fed on a high fat diet or being exposed 
to environmental stress (Kotelevtsev et al. 1997). Work has since been undertaken to 
try to localize the tissue or tissues responsible for this overall effect. Genetically 
modified mice over expressing 11βHSD1 in adipose tissue (Masuzaki, et al. 2001) 
revealed elevated glucocorticoid levels within adipose tissue yet unaltered circulating 
concentrations, mirroring findings in human obesity. The phenotype was additionally 
consistent with the metabolic syndrome with glucose dysregulation, hypertension 
and dyslipidaemia. Mice over expressing 11βHSD1 selectively in the liver developed 
similar adverse metabolic features of glucose dysregulation but lacked the 
development of obesity (Paterson, et al. 2004).  Liver specific knockout mice have 
additionally been generated which displayed mild improvement in glucose tolerance 
but limited effect on insulin sensitivity, adposity and weight (Lavery et al. 2012). 
These limited improvements in metabolic phenotype were disappointing in light of 
the knowledge of the significant contribution of liver to whole body cortisol 
regeneration by 11βHSD1 (Andrew et al. 2005; Basu et al. 2009). Further 
investigations have provided more encouraging results from liver specific knock 
down mice resisting  the development of hyperinsulinaemia and display normal 
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glucose tolerance despite treatment with glucocorticoids (Harno, et al. 2013). It is 
questionable whether this may be mediated by altered clearance of administered 
steroids. By comparing the effects of adipose specific and liver specific 11βHSD1 
knockout mice it is probable that dyslipidaemic effects of glucocorticoids are 
directed from adipose tissue whilst the development of glucose dysregulation is 
driven by the liver (Morgan et al. 2014).  
 
1.11 11βHSD1 inhibitors  
The concept of pharmacological inhibition for the treatment of the metabolic 
syndrome has been proven in genetically modified hyperglycaemic 
hyperinsulinaemic murine models with resultant reduction in endogenous glucose 
production, circulating insulin concentrations and improvement in dyslipidaemia 
(Alberts, et al. 2002). Studies have since progressed to human clinical studies.  
1.11.1 Non-selective inhibition 
Carbenoxolone was the first 11βHSD inhibitor to be trialled in humans. With 
evidence of increased whole body insulin sensitisation in healthy volunteers (Walker, 
et al. 1995), carbenoxolone was trialled in men with T2DM (Andrews, et al. 2003). 
After 7 days there was no effect on the rate of glucose disposal although the rate of 
glycogenolysis during hyperglucagonaemia was signficantly reduced.  As would be 
anticipated blood pressure rose due to the non-selective action of carbenoxolone on 
the isozyme 11βHSD2. Future development of carbenoxolone as treatment for 
T2DM was limited after failure to show an improvement on  glycosylated 
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haemoglobin (HbA1c) and with known adverse effects on blood pressure (Sandeep, 
et al. 2004).    
1.11.2 Selective inhibition 
The first selective 11βHSD1 inhibtor for clinical use was developed by Biovitrum 
with a thirty-fold higher selectivity for the type 1 isozyme (Alberts et al. 2002). In 
hyperglycaemic and hyperinsulinaemic mice, 7 days treatment resulted in reduced 
circulating glucose and insulin levels but with little impact on food intake and 
weight. Collaboration with Amgen led to the development of AMG-311 which 
entered phase II trials but in 2005 was discontinued (Jones RM 2012). With lack of 
success in clinical studies from whole body 11βHSD1 inhibition, work progressed 
targeting enzyme activity in adipose tissue. Biovitrum’s later compound, BVT-
116429 resulted in a 90% reduction in 11βHSD1 activity within adipose tissue 6 
hours post dose in mice (St. Jean, et al. 2007). In diabetes induced (KKAy) mice and 
in human adipocytes in vitro, tissue specificity was shown through the unique effect 
of this compound in elevating adiponectin production. After seven days treatment, 
basal insulin levels in mice were reduced but there was no improvement in insulin 
sensitivity. The limitation of adipose tissue specific inhibitors was apparent with a 
lack of reduction in hepatic gluconeogenesis independent of any alteration in fat 
mass or circulating lipids (Sundbom, et al. 2008).  
1.11.3 Phase 2 trial data for Type 2 Diabetes Mellitus 
Both Merck and Incyte have developed compounds which have reached phase II 
trials (Table 1.1) with beneficial effects on glycaemic control. Incyte’s compound 
INCB-13739 showed lipid lowering effects and increased insulin sensitivity in a 
phase I trial (Hawkins, et al. 2008) and reduction in HbA1c by 5.5 mmol/mol after 
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12 weeks in phase II trial (Rosenstock, et al. 2010). Improvement in HbA1c was 
greatest in those with poorest control and largest BMI at baseline supporting the need 
for appropriate patient selection.  
The concept of 11βHSD1 inhibitors as novel agents for the treatment of T2DM is 
evident with potential favourable cardiovascular risk reduction through alteration in 
lipids, blood pressure and body weight. The maximum benefit may require longer 
administration  than the currently studied 12 week drug exposure masking their full 
potential. Pfizer validated  pharmacodynamic biomarkers of 11βHSD1 inhibition in 
vivo through the use of urinary cortisol metabolites and the conversion of oral 
prednisone to prednisolone (Courtney, et al. 2008). Using gold standard tracer 
technique, the target effect of 11βHSD1 inhibition has been assessed for only one 
compound, AB-384. Using a primed continuous D4-cortisol infusion, enyme activity 
was suppressed in vivo by over 80% across whole body (Katz, et al. 2013). 
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Pharmaceutical agent         and study 
details 
Primary outcome Secondary outcomes  Other effects  
Rosenstock et al. Diabetes Care  2010 
(Rosenstock et al. 2010) 
INCB-13739 
302 patients with type 2 diabetes (mean BMI 
32kg/m2, mean HbA1c 8.6%) on metformin 
Randomised to one of 6 doses INCB-13739 
or placebo for 12 weeks  
Reduced HbA1c       
(-0.56%) 
 
Reduced fasting plasma 
glucose  (-1.3mM) 
Improved HOMA-IR 
(24%)  
Reduced body weight       
(-1kg) 
Reduced total cholesterol 
(-3%) 
No change in BP 
Plasma cortisol and salivary 
cortisol unaltered 
Elevated ACTH (100%), DHEAS 
(54%) and androstenedione (60%) 
In females elevated total 
testosterone but not FAI 
Feig et al. Diabetes, Obesity Metabolism  
2011(Feig, et al. 2011) 
MK-0916 
154 patients with type 2 diabetes (mean BMI 
32kg/m2, mean HbA1c 7.3%) with ≥ 1 
metabolic syndrome features 
Randomised to one of 3 doses MK-0916 or 
placebo for 12 weeks  
No effect on 
fasting plasma 
glucose  
Reduced HbA1c (-0.3%)         
No effect on post-prandial 
glucose    
Reduced body weight (-
1.8kg) with a trend for 
waist reduction  
Reduced BP (-8/5 mmHg) 
Increase LDL cholesterol 
(10%)  
Elevated DHEA (33%), 
androstenedione (22%) and 
testosterone (26%) 
No reported hirsutism or acne  
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Shah et al. J Am Soc Hypertension (Shah, et 
al. 2011)  
MK-0916 and MK-0736 
Hypertensive non-diabetic patients with BMI  
27 – 41kg/m2   (n= >50/group) or 20- 27kg/m2 
(n = 19/group)  
Randomised to one of 2 doses of MK-0736, 
one dose of MK-0916 or placebo for 12 
weeks 
Non significant 
reduction in sitting 
BP 
Reduction in daytime BP      
(-6/2 mmHg) 
Weight reduction (-1kg) 
Reduction LDL 
cholesterol (- <5%) 
Elevated DHEA (54%), 
androstenedione (42%), 
testosterone (57%)  
No effect hirsutism  or acne 
Freude et al. Diabetes, Obesity and 
Metabolism (Freude, et al. 2016) 
BI 135585  
72 men and post-menopausal women with 
T2DM with BMI 25-40 kg/m2 and HbA1c 
<8.5% 
Randomised to one of six doses of BI 135585 






ratio in urine).  
No  enzyme 
inhibition in ex 
vivo adipose tissue 
samples after 14 
days treatment  
Plasma glucose, HbA1c 
unchanged after 14 days 
Increased ACTH concentration and 
increased urinary cortisol 
metabolites.  
Increased DHEAS and 
androstenedione concentrations 
although majority still within the 
reference range and returned t 
baseline 10 days after 
discontinuation 
 


















Table 1.1 Results of published Phase II trials with selective 11βHSD 1 inhibitors for treatment of type 2 diabetes mellitus 
ACTH; adrenocorticotropic hormone; BMI: body mass index; BP: blood pressure; DBP: diastolic blood pressure; DHEA: dehydroepiandrosterone; DHEAS: 
dehydroepiandrosterone sulphate; FAI: free androgen index; HbA1c: glycosylated haemoglobin; LDL: low density lipoprotein; SBP: systolic blood pressure; 
THF: tetra-hydrocortisol; THE: tetra-hydrocortisone
Heise et al. Diabetes, Obesity and 
Metabolism (Heise, et al. 2014) 
RO-151 and RO-838 
110 men and women with T2DM BMI 26-42 
kg/m2 and HbA1c between 7 and 10% on 
metformin treatment  
Randomised to 10 or 400 mg RO-151, 50 or 
200 mg RO-838 or placebo in combination 
with netformin for 28 days 
No effect on mean 
daily plasma 
glucose or fasting 
plasma glucose 
concentrations  
Reduction in HbA1c with 
RO-151 (-0.37%) 
 
Dose dependent reduction 
in weight across all groups 
(between -0.86 to -1.67 
kg) 
Increase in trigylcerides 
(40%) and VLDL (25%) 
with high dose RO-838 
 
Increase SBP (1.4-5.1 mmHg) and 
DBP (1.5-4.5 mmHg) with high 
dose RO-838 
Reduction in SBP (mean -3.53 
mmHg) with low dose RO-151 
Dose dependent elevation in ACTH 
with RO-151 (44-69%) 
Increase DHEA, androstenedione 
with RO-151  
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1.11.4 Additional therapeutic effects of 11βHSD1 inhibition  
Cortisol dysregulation through the action 11βHSD1 has been implicated in the 
development of conditions associated with the metabolic syndrome and T2DM. Pre-
clinical studies have shown that 11βHSD1 inhibition prevents progression of 
atheromatous plaque disease and reduces deposition of cholesterol in the aorta 
(Atalar, et al. 2012; Hermanowski-Vosatka, et al. 2005). Such findings have not been 
replicated in humans although elevated 11βHSD1 in the ascending aorta of 
individuals with the metabolic syndrome and concomitant coronary artery disease 
provides circumstantial evidence for extrapolation from mice (Atalar et al. 2012). 
These beneficial effects on neointimal proliferation can also be utilised in the setting 
of peripheral artery atheromatous disease as has been shown in atherosclerotic prone 
Apo E knockout mice fed on a high fat western diet (Iqbal, et al. 2012). Since these 
findings were not replicated in the same study using C57B16 mice the mechanism of 
action may be local in the vessel wall or through systemic risk factors such as blood 
pressure.  
As well as their proliferative effect on intimal smooth muscle, glucocortcoids play a 
role in the inhibition of angiogenesis at sites of tissue ischaemia. Mice with global 
11βHSD1 deficiency have exaggerated angiogenesis in skin wounds following 
subcutaneous sponge insertion, and in myocardium following coronary artery 
ligation (Small, et al. 2005). This has been associated with protection from heart 
failure following myocardial infarction in mice (McSweeney, et al. 2010). If 
replicated using pharmacological 11βHSD1 inhibitors, this may provide additional 
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benefits to treating patients with T2DM post cardiovascular event or those with 
chronic foot ulcerations.  
Deletion or inhibition of 11βHSD1 has been observed to reduce age related cognitive 
dysfunction in mice (Sooy, et al. 2010; Yau, et al. 2001). In human clinical studies 
the non selective inhibitor carbenoxolne improved memory in individuals with and 
without T2DM (Sandeep et al. 2004). More recently Abbott developed a selective 
11βHSD1 inhibitor which reached phase II clinical trial. The primary outcome was 
change from baseline in cognitive function and memory as assessed by Alzheimer’s 
Disease Assessment Scale (ADAS). Neither dose trialed resulted in improvement of 
cognitive function compared to placebo, but it appears the compound did not 
penetrate central nervous system sufficiently to achieve adequate inhibition of brain 
11βHSD1. Preclinical studies have provided evidence of efficacy in target enzyme 
inhibition (Liu, et al. 2013) and 11βHSD1 inhibition in a mouse model of 
Alzheimer’s disease prevented cognitive decline with chronic treatment (Sooy, et al. 
2015). 
Patients with T2DM are at increased risk of developing nonalcoholic steatohepatitis 
with potential development of liver fibrosis and cirrhosis. Hyperactivity of the HPA 
axis has been observed in the setting of non-alcoholic fatty liver disease (NAFLD) 
implicating subclinical hypercortisolism as the pathogenic mechanism (Targher, et 
al. 2006). Roche have pursed this with the progression of one of their compounds to 
phase II trial for the treatment of NAFLD (Stefan, et al. 2014). Twelve weeks 
treatment resulted in a significant reduction in liver fat content in overweight (BMI > 
27 kg/m2) individuals with compounding insulin resistance.   
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1.11.5 Toxicity of 11βHSD1 inhibitors 
In general 11βHSD1 inhibitors have been well tolerated over 12 week’s 
administration in clinical studies. Concerns remain about potential effects on whole 
body homeostasis with their use through alteration of HPA axis. With reduced tissue 
glucocorticoid synthesis, net cortisol clearance is increased. As a result a 
compensatory upregulation of the HPA axis is likely to ensue through stimulation of 
CRH release and ACTH production. Studies have confirmed that this maintains 
whole body circulating cortisol (Hawkins et al. 2008; Rosenstock et al. 2010) but at 
the expense of activating other steroidogenesis pathways, notably adrenal androgens. 
Whether this effect on steroidogenesis is of clinical significance remains unclear. 
The greatest impact is likely to be in female patients resulting in hirsutism, acne and 
menstrual irregularities. Such effects have been shown to be reversible upon 
withdrawal (Feig et al. 2011) although prescription is likely to be avoided in females 
of child bearing age.  
Concern has been raised whether reducing peripheral cortisol concentrations may 
impair the body’s ability to respond to stress, infection and inflammation. Target 
individuals with poorly controlled T2DM are already at higher risk of infection 
which could be compounded by such agents. Any increased incidence of infective 
symptoms in studies to date has been mild and localized (Courtney et al. 2008). With 
co-administration of hypoglycaemic agents the risk of developing and the response to 
hypoglycaemia may be impaired which would require close monitoring (Harno and 
White 2010). With structural homology, neuroactive steroids and oxysterols are 
metabolized by 11βHSD1. Whole body inhibition may therefore have resultant 
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consequences on neurotransmission and bile acid synthesis (Odermatt and Nashev 
2010). 
1.11.6 Questions for the efficacy of 11βHSD1 inhibition 
With promising results from in vitro data (Schweizer, et al. 2003), it is of interest to 
consider whether post transcriptional regulation of 11βHSD1 is different in vivo in 
diabetic individuals or whether other factors may be masking their full effect. With 
few published clinical studies recruiting diabetic patients much remains uncertain 
about 11βHSD1 activity in the context of hyperglycaemia and its treatment.  
As a novel agents for the treatment of T2DM it is likely that their prescription will be 
second or third line alongside well established therapies for diabetes such as 
metformin or gliclazide.  
Metformin has been available for over fifty years and is the most frequently 
prescribed anti-diabetic treatment worldwide.  Its popularity stems from additional 
benefits such  as reduction in caloric intake (Glueck, et al. 2001), hypothesized to be 
due to increased transcription of the incretin hormone, glucagon-like peptide 1 (GLP-
1) (Maida, et al. 2011), with consequential reduction in weight (Salpeter, et al. 2008). 
Moreover, this weight reduction has been observed to be predominantly due to 
reduction in adipose tissue rather than muscle mass (Stumvoll , et al. 1995). 
Evidence for beneficial effects on cardiovascular risk factors such as blood pressure 
(Giugliano, et al. 1993; Hermann, et al. 1994) and circulating lipid levels (Hermann 
et al. 1994; Salpeter et al. 2008) as well as hard end-point cardiovascular disease 
(Boussageon, et al. 2012; Hemmingsen, et al. 2012; UKPDS 1998) has been disputed 
between studies.       
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The glucose lowering effect of metformin is thought  to be through inhibition of 
gluconeogenesis by the liver (Shaw, et al. 2005) and increased glucose disposal into 
skeletal muscle (McIntyre, et al. 1991). The principle cellular membrane transporters 
of metformin, solute carrier family 22 members (SLC22A), are highly expressed in 
the liver where the effects of metformin are thought to predominate. By increasing 
activation of insulin receptor and insulin receptor substrate (IRS-2) as well as 
promoting translocation of glucose transporters (Gunton, et al. 2003), metformin is 
thought to improve cellular sensitivity to insulin with resultant suppression of 
gluconeogenic pathways. The gluconeogenic effect of glucagon is additionally 
blocked by metformin further reducing circulating glucose concentrations (Miller, et 
al. 2013). All of this results in improved utilization of glucose and as a result 
reduction in the requirement of insulin secretion.      
At a cellular level, metformin inhibits complex 1 of the mitochondrial electron 
transport chain (Pernicova and Korbonits 2014) causing a reduction in adenosine 
triphosphate (ATP) and increase in adenosine monophosphate (AMP) production. 
This drop in ATP inhibits the action of glycogen in synthesizing cyclic adenosine 
monophosphate (cAMP) and drives the action of 5’-AMP-activated protein kinase 
(AMPK). AMPK acts as a cellular ‘fuel gauge’ driving catabolic pathways, such as 
fatty acid oxidation (Merrill, et al. 1997) and switching off ATP consuming 
pathways such as gluconeogenesis. AMPK additionally increases the activity of 
insulin receptor function improving tissue sensitivity and stimulates the migration of 
glucose transporters to the cell membrane (Gunton et al. 2003).  
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The involvement of AMPK in the mechanism of action of metformin has been 
questioned. Using AMPK deficient murine models, metformin has been observed to 
disrupt hepatic gluconeogenic pathways in an AMPK- and transcription-independent 
manner (Foretz, et al. 2010). In accordance with this a further study showed a direct 
effect of metfornin on increasing AMP, without the involvement of AMPK, thereby 
antagonizing the effect of glucagon on cAMP and resulting in reduced activation of 
protein kinase A. Down-stream kinases fail to be phosphorylated disrupting 
gluconeogenic pathways involving  phosphoenolpyruvate carboxykinase (PEPCK) 
and glucose-6-phosphatase (Miller et al. 2013).  
In contrast, the mechanism of action of alternative oral hypoglycaeic agents such as 
gliclazide is well detailed. Gliclazide is thought to stimulate insulin secretion through 
activation of the sulphonylurea receptor on pancreatic β cells. It may have addition 
beneficial effects on hepatic glucose production and post insulin receptor signaling 
(Campbell, et al. 1991a). 
With the knowledge of tissue specific dysregulation of 11βHSD1 in the setting of 
T2DM, it is postulated whether 11βHSD1 inhibitors may be more efficacious if they 
target specific tissues. As discussed previously (Section 1.10), knockout of the 
enzyme in liver in murine models showed some improvement in glucose tolerance 
but with limited benefit on weight reduction. No genetically modified models of 
adipose specific 11βHSD1 knockout have been generated. Biovitrum’s compound, 
BVT-116429 was observed to have high availability in adipose tissue displaying 
90% reduction in 11βHSD1 6 hours post dose in male mice (St. Jean et al. 2007). In 
a diabetic KKAy mouse model, this agent reduced fasting glucose after 10 days 
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treatment (Sundbom et al. 2008). Adiponectin levels increased suggesting adipose- 
specific mechanism of action. Disappointingly body weight remained steady with no 
significant reduction in total body adiposity. Additionally, although basal insulin 
levels were reduced, an insulin tolerance test did not show any significant 
improvement in sensitivity, although this was only over a 10 day treatment period. 
11βHSD1 inhibition has been observed using the same compound in cultured 
primary human adipocytes in vitro although it has not progressed to phase 2 trials. 
There is therefore as yet no strong evidence for improved efficacy with tissue 
specific inhibition of 11βHSD1 for the treatment on T2DM.      
Early experiments observed 11βHSD1 to be a dehydrogenase enzyme in experiments 
in homogenised rat liver (Lakshmi and Monder 1988). Further work using intact cells 
revealed predominant reductase activity (Jamieson et al. 1995). These conflicting 
results were thought to be due to altered availability of co-substrate but this has never 
been proven. Bidirectional activity was observed in vivo in adipose tissue through the 
use of cortisol and cortisone tracers (Wake et al. 2006). Despite this it has been 
suggested that 11βHSD1 acts solely as a reductase enzyme in vivo and 
dehydrogenase enzyme in vitro. It is unquestionable that in metabolically active 
tissue 11βHSD1 acts primarily as a reductase enzyme. Whether this is influenced by 
whole body glucocorticoid dysregulation such as with HPA axis alteration in the 
presence of the metabolic syndrome (Reynolds et al. 2001a) is unknown. 
Additionally we have observed tissue specific 11βHSD1 reductase activity in relation 
to obesity and T2DM but we do not know the impact on corresponding 
dehydrogenase activity.    
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Work undertaken within our department has confirmed bidirectional 11βHSD1 
activity in adipose tissue and skeletal muscle in healthy male volunteers (Hughes et 
al. 2012). Across splanchnic tissue, there was a preponderance of reductase activity 
at a ratio of 3:1. In adipose tissue there was a slight shift towards dehydrogenase 
activity (reductase: dehydrogenase; 1:1.3) with equal rates across skeletal muscle. It 
can be hypothesised that at a cellular level, cortisol regulation may exist through an 
ability to regulate these opposing reactions. A greater understanding of regulation of 
cortisol at an intracellular level may allow the development of more efficacious 
pharmacological agents for the treatment of T2DM and coexisting features of the 
metabolic syndrome.  
 
1.12 Hypothesis 
(a) Metformin downregulates 11βHSD1 activity masking the efficacy 11βHSD1 
inhibitors for the treatment of type 2 diabetes mellitus 
(b) Measurement of total cortisol (free plus bound) underestimates the 
contribution of 11βHSD1 activity to the circulating plasma pool 
(c) 11βHSD1 acts as a bidirectional enzyme in vitro and in vivo 
(d) 11βHSD1 acts predominately as a reductase enzyme in obese individuals 









This thesis seeks to investigate the control of intracellular cortisol and cortisone 
through the action of 11βHSD1 particularly focusing on 
(a)  whether metformin treatment acts through 11βHSD1 to regulate cellular 
cortisol obscuring the efficacy of inhibitors   
(b) whether clinical studies have underestimated the contribution of 11βHSD1 to 
the circulating pool by addressing total rather than free hormone and 
(c) the impact of recycling between cortisol and cortisone in whole body, 



















Chapter 2    49 
 
 
2.1 Introduction to materials and methods 
All measurements and samples collected during clinical studies were undertaken by 
the author except those declared in Section 3.4. Assays in routine departmental use 
were optimised as described below for analysis of deuterated tracers as well as 
endogenous glucocorticoids in particular for measurement in human plasma and cell 
culture medium. Where stated, room temperature corresponds to a temperature of 18-
22 ⁰C.  
 
2.2 Equipment 
2.2.1 Laboratory equipment 
2.2.1.1 Centrifuges 
2.2.1.1.1 Clinical Studies 
Eppendorf Centrifuge 5810 R (Eppendorf AG, Hamburg, Germany). 
2.2.1.1.2  Free cortisol method development 
 Heraeus Sepatech Biofuge 13 centrifuge (Heraeus, Hanau, Germany). 
2.2.1.1.3 Cell Culture 
Heraeus Labofuge 400 R Centrifuge (Heraeus, Hanau, Germany). 
2.2.1.2 pH meter 
Thermo Orion 410 A (Fisher Scientific, Loughborough, UK). 
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2.2.1.3 Plate rotator 
iEMS incubator/shaker (Thermo Scientific Inc, Waltham, MA). 
2.2.1.4 Incubated shaker 
(a) Barnstead Lab Line Max Q 4000 Orbital Shaker (Fisher Scientific, 
Loughborough, UK). 
(b)   Gallenkamp Orbital Shaker Incubator. 
2.2.1.5 Oven  
Memmert heating cabinet (Memmert, Germany). 
2.2.1.6 Plate reader 
Optimax tuneable microplate reader (Molecular Devices, Sunnyvale, CA). 
 
2.2.2 Equipment for clinical studies 
2.2.2.1 Bioelectrical impedence  
OMRON Healthcare (UK) Ltd, Henfield, UK. 
2.2.2.2 Blood pressure and pulse measurement 
OMRON Healthcare Europe BV, Hoffddorp, NL. 
2.2.2.3 Filtered red light  
KL 2500 LCD (Schott UK Ltd., Stafford, UK). 
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2.2.2.4 Plethsmograph 
EC6 or EC4 plethsmography coupled with E20 rapid cuff inflator (Hokanson, WA, 
USA). Data displayed and analysed using Powerlab 4120 or 2120 and LabChart® 
Reader (Version 7.3) (AD Instruments, Oxford, UK).  
2.2.2.5 Gamma counters  
2.2.2.5.1 Xenon dose measurement for clinical study 
Amersham radioisotope calibrator ARC-120. 
2.2.2.5.2 Blood flow measurement  
GMS411 Mediscint gamma counter (John Caunt Scientific Ltd, Bury, UK) supported 
by GMS411 Data Manager Version 1.2.0. 
2.2.2.5.3 Laboratory cortisol radioimmunoassay 
Wallac Wizard 1470 Gamma Counter.  
 
2.3 Source of Materials  
All reagents were obtained from Sigma (Poole, UK) unless stated otherwise. 
2.3.1 Drugs for Clinical Studies 
2.3.1.1 Stable isotopically labelled tracers 
All stable isotopically labelled deuterated tracers were obtained from Cambridge 
Isotope Laboratories (CIL, Andover, MA.). Chemical and isotopic purity are as per 
manufacturer certificate of analysis.    
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2.3.1.1.1 D4-cortisol  
9,11,12,12-[2H]4–cortisol powder; >98% and 98.6% isotopic enrichment as 
determined by gas chromatography mass spectrometry.  
2.3.1.1.2 D2-cortisone  
1,2-[2H]2-cortisone powder; >96.3% purity and 98% isotopic enrichment as 
determined by thin layer chromatography (TLC).   
2.3.1.2 Unlabelled steroids 
2.3.1.2.1 Hydrocortisone 
Hydrocortisone sodium hemisuccinate (Solu Cortef) (Pharmacia, Belgium). 
2.3.1.3 Diluents 
2.3.1.3.1 Saline 
 Sodium Chloride (0.9% w/v) (Baxter, Newbury, UK), 154 mmol Sodium and 154 
mmol Chloride per 1000 mL.  
2.3.1.3.2 Pharmaceutical grade ethanol  
Ethanol (90-100% v/v) Torbay manufacturing unit, Paignton, UK. 
2.3.1.4 Hyperinsulinaemic euglycaemic clamp 
2.3.1.4.1 Insulin 
Actrapid (NovoNordisk, Crawley, UK), 100 units per mL.  
2.3.1.4.2 Dextrose 
Dextrose (20% w/v) (Baxter, Newbury, UK). 
2.3.1.5 Dexamethasone tablets  
Auden McKenzie (Pharma division) Ltd (a subsidiary of Actavis Ltd), Middlesex, 
UK. 
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2.3.1.6 Cortisone tablets 
Martindale Pharma, Buckinghamshire, UK. 
2.3.1.7 Radioactive substances 
2.3.1.7.1 133Xenon 
133Xenon gas (USP grade; >99.5% purity) (Nordion, Ottawa, Canada). Specific 
activity 0.00667 mCi per µL. 
 
2.3.2 Drugs for in vitro assays 
2.3.2.1 Stable isotopically labelled tracers 
2.3.2.1.1 D4-cortisol 
9,11,12,12-[2H]4–cortisol powder (Cambridge Isotope Labotatories, Andover, MA) 
as above (2.3.1 Drugs for Clinical Studies). 
2.3.2.1.2 D3-cortisol 
9, 12,12 [2H]3-cortisol powder (Cambridge Isotope Labotatories, Andover, MA). 
2.3.2.1.3 D8-cortisone  
2,2,4,6,6,9,12,12 [2H]8-Cortisone Santa Cruz Biotechnology Inc (Heidelberg, 
Germany). 
2.3.2.2 Unlabelled steroids 
Cortisol, cortisone, corticosterone were obtained from Sigma (Poole, UK), 
epi-cortisol and epi-corticosterone were obtained from Steraloids (Newport, RI).  
All of the above were made up in HPLC grade methanol at a final concentration of 
1mg/mL and stored at -20 ⁰C. 
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2.4 Cell Culture 
2.4.1 Reagents  
2.4.1.1 Fetal Calf Serum 
Fetal calf serum was deactivated by heating at 60 ⁰C for 30 minutes for laboratory 
use (Lonza, Slough).  
2.4.1.2 Medium 
Dulbecco’s Modified Eagle’s Medium (DMEM) (88%) containing 4.5 g/L glucose 
(Lonza, Slough, UK).  
 
2.4.2 Medium Preparation 
2.4.2.1 Cell growth medium 
Fetal calf serum (10% v/v), Penicillin-Streptomycin (0.5% each v/v) (Gibco, Paisley, 
UK) and glutamine (1% v/v; 2mM) (Gibco, Paisley, UK) were added to DMEM.  
2.4.2.2 Stripped steroid medium 
As per cell growth medium but exchanging fetal calf serum with that stripped of 
steroid (section 2.4.4.2).  
 
2.4.2.3 Medium for assay 
As per cell growth medium except fetal calf serum omited.  
2.4.2.4 Freezing medium 
Fetal calf serum (50% v/v 25 mL) (Lonza, Slough, UK) and dimethyl sulfoxide (10% 
v/v 5 mL) (Sigma, Poole,UK) added to  DMEM (40% v/v 20 mL).  
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2.4.2.5 Other reagents 
2.4.2.5.1 Phosphate buffered saline  
PBS (Lonza, Slough, UK). 
2.4.2.5.2 Charcoal 
Dextran coated charcoal. 
2.4.2.5.3 Trypsin 
Trypsin (200 mg/L). 
2.4.2.5.4  Ethylenediaminetetraacetic acid (EDTA)  
EDTA (Lonza, Slough, UK). 
2.4.2.5.5 Poly-D-lysine hydrobromide 
Poly-D-lysine.  
 
2.4.3 Source of cells 
Human embryonic kidney cells stably transfected with gene coding for human 11 β-
hydroxysteroid dehydrogenase type I (HEK293-11βHSD1) were obtained from Drug 
Discovery Core, University of Edinburgh (Webster and Pallin 2007). Cells were 
frozen in aliquots (in 1 mL freezing medium) at -80 ⁰C for 48 hours before being 
transferred to liquid nitrogen for long term storage. These were thawed rapidly upon 
requirement. 
 
2.4.4 HEK293-11βHSD1 cell culture 
Cells were maintained in cell culture flasks [(Corning, NY, USA); 75cm3] pretreated 
with poly-D-lysine and using growth medium (section 2.4.2.1). Standard tissue 
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culture conditions (37 ⁰C; 95% O2, 5% CO2) were used. Cells were passaged when 
confluent (approximately twice weekly). Cells were used at 3rd or 4th passage for 
assays.  
2.4.4.1 Cell passage 
Cell culture medium was removed from the culture plate and the cells were washed 
with phosphate buffered saline (5 mL). The cells were detached from the plate using 
trypsin (3 mL) and were shaken off after a 5 minute incubation period in standard 
conditions. The trypsin was deactivated using 7 mL of cell growth medium. 
Maximum cell recovery was ensured by rinsing the plate with medium during 
transfer of the cells into a 50 mL falcon tube. The cells were pelleted by 
centrifugation (800 x g; 22 ⁰C) for 5 minutes and subsequently re-suspended in an 
appropriate volume of medium for division between flasks or wells. 
2.4.4.2 Steroid removal from serum or plasma using charcoal 
A suspension of dextran coated charcoal in serum or plasma (1% w/v) was stirred at 
4 °C for 16 h. The suspension was filtered once through 3 filters (1.2, 0.45 and 0.2 
μm diameter pores). The stripped serum or plasma was aliquoted and stored (-20 °C) 
until required. 
 
2.4.5 Experimental conditions 
HEK 293-11βHSD1 cells were trypsinised for removal from culture flasks (as per 
cell passage above) and re-suspended in 10 mL cell growth medium. An aliquot (200 
μl) was diluted (1 in 5; total 1 mL) before being counted on a haemocytometer. One 
million cells were seeded into each well of a 12 well plate (Costar 12 well cell 
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culture plate, Corning, NY, USA).  Additional cell growth medium was added (total 
2 mL per well). The plates were incubated for 24 hours under standard conditions.  
Medium was removed and cells were washed with 1 mL phosphate buffered saline 
(PBS).  PBS was removed and replaced with steroid stripped medium (2 mL) and 
incubated for 24 hours.  Subsequently cells were washed in further PBS (1 mL). 
 
2.5 Free Cortisol Assay 
2.5.1 Materials 
2.5.1.1 Parafilm  
Parafilm (Pechiney Plastic packaging Companty, Chicago, USA). 
2.5.1.2 Dialysis tubing 
12-14 kDa, width 19 mm, approx length 30 m (Medicell, London, UK). 
2.5.1.3 Ultrafiltration Units 
Amicon Ultra-2 device (Merck, Watford, UK). 
 
2.5.2 Reagents  
2.5.2.1 Phosphate Buffered Saline 
To ensure physiological pH of 7.4, phosphate buffered saline (PBS) was made in the 
laboratory for use in free cortisol assay.  Phosphate Buffer (0.05 M) / Sodium 
Chloride (0.15 M) was prepared by adding KH2PO4 (1M, 7.6 mL), K2HPO4 (1M, 
42.4 mL) and NaCl (5M, 30 mL) to ultrapure water (920 mL). Acidity was measured 
and pH adjusted by adding KH2PO4 (acidic) or K2HPO4 (basic) drop wise until pH 
7.4 was achieved.  
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2.5.2.2 PBS gelatin  
Gelatin (Hydrolysed Gelatin (Byco™ A), Croda, Goole, UK ) (1% w/v) dissolved in 
PBS.  
2.5.2.3 Ethylediaminetetraacetic (EDTA) acid disodium salt dihydrtate 
EDTA sodium.  
2.5.2.4 Ultrapure water 
Milli-Q® water purification system (Millipore UK, Hertfordshire, UK).  
2.5.2.5 Dialysis tubing preparation 
De-ionised water containing sodium bicarbonate (2% w/v 10 mg) and EDTA sodium  
(1mM, 146.12 mg).  
2.5.2.6 Dialysis tubing preservative 
Ultrapure water containing 0.1% Bronidox L5 (0.1% (v/v), 500 μL) (Cognis, 
Ludwigshafen, Germany).  
 
2.5.3 Samples and Reagents  
2.5.3.1 Plasma   
Plasma was obtained from clinical studies following ethical approval and informed 
consent. Plasma used for method development was obtained following ethical 
approval from the Scottish National Blood Transfusion Service, Edinburgh 
(Submission number 12-05).  
2.5.3.2 Steroid from human plasma 
Human plasma (7 mL) was stripped of steroid using dextran coated charcoal (70 mg, 
1% w/v). The suspension was stirred at 4 °C for 16 hours before being filtered 
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through consecutively smaller filters (1.2, 0.45 and 0.2 μm diameter pores). Aliquots 
of stripped plasma (1.5 mL) were stored (-20 °C) until required.  
 
2.5.4 Equilibrium dialysis 
2.5.4.1 Dialysis tubing preparation 
A length of desiccated dialysis tubing was cut and heated in dialysis tubing 
preparation reagent (see 2.3.4.2) at 80 ⁰C for 30 minutes. The tubing was rinsed 
thoroughly in de-ionised water before being stored in preservative (see 2.5.2.6).  
2.5.4.2 Separation of free from bound cortisol by equilibrium dialysis 
Equilibrium dialysis units were developed as a modified version of the technique 
instituted by Reinard et al. (Reinard and Jacobsen 1989). Lids of microdialysis tubes 
(Eppendorf 1.5 mL) were cut and retained. These were filled with phosphate 
buffered saline (250 μL) (see 2.3.4). The apex of the microdialysis tube was cut (0.5 
cm from the tip).  Microdialysis tubing was removed from its preservative and 
washed in deionised water. Strips (1.5 cm x 1.9 cm) were cut and placed over the 
PBS gelatin filled lid ensuring complete coverage. The dialysis membrane was held 
in place by rejoining the body of the tube to the lid. Plasma (1 mL) was pipetted on 
top of the dialysis membrane and the unit was sealed with parafilm (Figure 2.1). 
Equilibrium dialysis units were held securely in a plastic beaker and incubated for 16 
hours (37 ⁰C, rotated as 180 rpm). After this time the dialysate was removed from the 
lid and aliquoted into a glass tube for extraction (section 2.6). Where volumes of 
plasma greater than 1 mL were required multiple units were set up and the dialysate 
was pooled together. 
 







Figure 2.1 Equilibrium dialysis set up 
 
2.5.5 Ultrafiltration 
2.5.5.1 Separation of free from bound cortisol by ultrafiltration 
Ultrafiltration units were filled with 1 mL plasma and centrifuged at 1500 x g for 30 
minutes at 37 ⁰C. The filtrate was collected and aliquoted.  
 
2.5.6 Enzyme-linked immunosorbent assay 
Salivary cortisol ELISA (Salimetrics, Suffolk, UK) was used since standard samples 
spanned a lower range of concentrations compared to alternative ELISA kits which 
was necessary for quantification of free cortisol.  
Manufacturer’s protocol was adhered to. Samples and standards (25 μL) were 
pipetted into the desired number of wells. Enzyme conjugate (containing antibody) 
was prepared by diluting stock solution 1:1600 before 200 μL aliquots were added to 
each well. Mixing was ensured through the use of a plate rotator (5 minutes at 500 
rpm) (section 2.2.1.3) followed by a further 55 minutes at room temperature. The 
plate was washed 4 times with wash buffer (300 μl) provided by the manufacturer. 
The plate was blotted on absorbent paper to remove any residual antibody. Substrate 
cut 
cut 
PARAFILM ® used as lid 
Sample 
Dialysis membrane 
Lid with PBS 1% Gelatin  
(a)Microcentrifuge tube (b)Top and lid cut off (c)Equilibrium dialysis unit set up 
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solution (200 μl) was added and mixed using the plate rotator (5 minutes at 500 
rpm). Incubation (dark conditions at room temperature) for 25 minutes allowed 
maximum enzymatic conversion of the substrate. The reaction was stopped using 
acidic stop solution and read using a plate reader.  
One well supplied by the manufacturer was used for non-specific binding and one 
well contained no standard or sample acting as a blank. Where detectable, non-
specific binding was subtracted from all standards and samples. All samples and 
standards were performed in duplicate. Intra-assay relative standard deviation was 
accepted if < 10%.    
Standards ranged 0.33 to 82.77 nmoles/L (6 standards). A 4 parameter logistic 
nonlinear regression curve was plotted of optical density against concentration. 
Coefficient of determination of the curve was accepted if r2 > 0.9.   
 
2.6 Extraction of glucocorticoids from sample 
matrices  
2.6.1 Cell culture medium  
Samples were thawed at room temperature (30 mins) before an aliquot (500 μL) was 
enriched with internal standard (epi-cortisol and D8 cortisone - mass used detailed in 
relevant section). Glucocorticoids were extracted using Sep-Pak C18 Classic 
Cartridges (360 mg, Waters Millipore, Watford, UK) pre-conditioned using methanol 
(5 mL) and water (5 mL). Sample was loaded and unwanted hydrophilic compounds 
were washed through with water (5 mL) before the steroid was eluted in methanol (2 
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mL). The organic solvent was removed by heating (60 ⁰C) under a stream of oxygen 
free nitrogen (OFN). The residue was reconstituted in water (200 μL) and ethyl 
acetate (2 mL). The organic layer was transferred into a clean glass tube and the 
solvent removed by heating (60 ⁰C) under a stream of OFN. Extracted steroids were 
reconstituted in mobile phase (100 μL water: acetonitrile 70:30) and transferred to 
LC-MS/MS vials for analysis. Where immediate analysis was not undertaken 
samples were stored at -20 ⁰C.  
Standards were produced for quantification by diluting stock solutions of the various 
glucocorticoids (1 mg/mL) into medium for assay (500 μL) ranging from 2 ng/mL to 
250 ng/mL. Epi-cortisol and D8 cortisone (100 ng/mL) were used as internal 
standard. A blank sample containing internal standard only was included. Extraction 
was performed as set out above.  
 
2.6.2 Plasma 
2.6.2.1 Extraction of steroids from plasma   
Plasma samples were defrosted at room temperature. Volumes (as specified in each 
section) were aliquoted into glass tubes. Internal standard was added (see relevant 
section for mass) and incorporated by vortex mixing. Chloroform was added (10:1 
ratio; 10 mL chloroform: 1 mL plasma) and vortex mixed. The plasma layer was 
removed using a glass Pasteur pipettes and the chloroform layer transferred into a 
clean glass tube. This process was repeated to ensure the removal of all plasma 
proteins. The organic solvent was dried under OFN at 60 ⁰C. Residual steroids were 
reconstituted in mobile phase (70:30 water: acetonitrile; 75 – 100 μl) before being 
transferred to an LC-MS/MS vial for analysis.  
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2.6.2.2 Preparation of standards for LC-MS/MS analysis 
Stock solutions of the desired glucocorticoids (1 mg/mL) were diluted in methanol 
and mixed in combinations allowing for potential interference between isotopes on 
analysis by LC-MS/MS (separating D4-cortisol and D3-cortisol as well as cortisone 
and D2-cortisone). Aliquots were pipetted into glass tubes producing a concentration 
range as specified in each section. Internal standard identical to that used in the 
samples was added. The volume of each standard was made up to 200 μL with water. 
These were thoroughly mixed before chloroform was added (10:1 ratio; 2 mL 
chloroform; 200 μL standard) was added. The aqueous layer was removed and the 
chloroform layer was transferred into a clean glass tube. The organic solvent was 
removed by heating at 60 ⁰C under OFN. The residue was reconstituted in mobile 
phase (70:30 H2O: acetonitrile; volume as set out in specific section) and transferred 
into an LC-MS/Ms vial. If analysis was not performed immediately standards were 
frozen at -20 ⁰C as per samples.  
Enrichment curves were also generated representing a tracer to tracee ratio of 0 to 
100% (D4 cortisol: cortisol and cortisone, D2 cortisone: cortisone and D4 cortisol: 
D3 cortisol). This allowed assessment of equivalent ionization of deuterated and 
unlabelled glucocorticoids during LC-MS/MS. Adjustment for differential ionization 
was only required where stated. Standards for the enrichment curve were produced 
using an identical method to the production of the standard curve for concentration as 
set out above but with consistent concentrations of cortisol and cortisone across the 
curve and with an incremental increase in D4-cortisol as exemplified below. 










Table 2.1 Standard and enrichment curve 
Example of a standard and enrichment curve for Cortisol and D4-cortisol quantification in plasma. In the standard curve, increasing masses of 
glucocorticoids are aliquoted against a fixed internal standard (epi-cortisol) from which the ratio is used to quantify unknown masses from samples. The 
enrichment curve provides a ratio of the mass of tracer (e.g D4-cortisol) to tracee (Cortisol). 
STANDARD CURVE ENRICHMENT CURVE 
Epi-cortisol (ng) Cortisol (ng) D4-Cortisol (ng) Tracer:tracee ratio 
(%) 
Cortisol (ng) D4-cortisol (ng) 
500 0 0 0 500 0 
500 2 1 2.5 500 25 
500 5 2.5 5 500 50 
500 10 5 7.5 500 75 
500 20 10 12.5 500 125 
500 30 15 25 500 250 
500 50 25 50 500 500 
500 100 50    
500 200 100    
500 300 150    
 400 200    
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2.7 Chromatographic Analysis 
2.7.1 Instrument 
LC-MS/MS:Waters Acquity™ UPLC (Manchester, UK)  along with autosampler 
interfaced with a triple quadrupole ion trap mass spectrometer (ABSciex QTRAP® 
5500 (Warrington, UK)). System operation and analyte quantification was performed 
using Analyst® software version 1.5.1.  
 
2.7.2 Run conditions 
Separation of deuterated and unlabelled glucocorticoids was achieved with the use of 
a Sunfire™ C18 column (3.5 μm, 2.1 x 100 mm) at 10 ⁰C protected by a Hypersil 
C18 guard cartridge (10x3 mm, 3 µm, ThermoElectron, Hemel Hempstead, UK) . 
Elution with narrow distinctly separated peaks was achieved using mobile phase 
(0.1% formic acid in H2O and 0.1% formic acid in acetonitrile) at a flow rate of 0.5 
mL per minute. An isocratic solvent system (70:30 H2O: acetonitrile v/v) was used 
for sample elution (6 minutes per sample).  
Ionisation was performed in positive atmospheric pressure chemical ionisation mode. 
Mass transitions were detected using tandem mass spectrometry (curtain gas 25 psi, 
collision gas pressure medium, spray voltage 5kV source temperature 550 ⁰C). Mass 
transitions detected are set out in Table 2.2 below.    
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Figure 2.2 Chromatograph of deuterated and unlabelled glucocorticoids  
 Distinctive peak areas for each analyte separated according to mass to charge (m/z) ratio and distinctive transition for each parent ion   
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potential     
(V) 
Collision 





Cortisol 363 → 121 131 19 14 
Cortisone 361 → 77 166 99 36 
D4-cortisol 367 → 121 121 25 20 
D3-cortisol 366 → 121 121 27 20 
D3-cortisone 364 → 164 166 31 14 
D2-cortisone 363 → 165 166 31 22 
Epi-cortisol 363 → 77 141 101 14 
D8-cortisone 369 → 169 186 29 28 
Table 2.2 Chromatographic conditions for LC-MS/MS   
D; deuterium: m/z; mass to charge ratio: V; volts  
 
2.7.3 Data analysis  
Analyst® software was utilised to integrate area under the peak for each analyte and 
internal standard. The ratio of analyte peak area against its corresponding internal 
standard was used for quantification against a standard curve. A line of best fit (y = 
mx+c) was drawn after plotting known steroid concentrations (x axis) against the 
corresponding analyte to internal standard peak area ratio (y axis). A regression 
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coefficient (r2) of >0.9 was accepted for each standard curve. Where D3-cortisol and 
D2-cortisone were quantified, separate standard curves were prepared to avoid 
interference between isotopologues. Enrichment curves were created to ensure 
corresponding ionisation between endogenous and deuterated steroids. Where this 
proved not to be the case steroid concentrations were adjusted accordingly as stated 
in the relevant section below. Arithmetic correction for background heavy isotopes 
was employed where necessary.   
 
2.8 Cortisol radioimmunoassay 
(Cortisol 125Iodine radioimmunoassay, MP Biomedical, Hessen, Germany).  All 
samples and reagents were brought to room temperature. Samples, standards (range 0 
to 100 µg/dL) and controls were dispensed (25 µL) into individual tubes pre-coated 
with antibody. Competitive binding was allowed by incubating sample and 
radiolabelled ligand (Cortisol-125I 1 mL) for 45 minutes (at 37 °C). Unbound ligand 
was decanted by inverting the tubes in a short sharp movement and swabbing the 
opening of the inverted tube with a cotton bud. Bound 125I was measured using a 
gamma counter. All samples and standards were performed in duplicate and the 
mean counts per minute for each sample and standard was used for analysis. 
Variability was accepted if relative standard deviation was <10%. The zero standard 
(0 µg/dL) was used as ‘total’ counts from which all samples and standards were 
subtracted for generation of standard curve and as such determination of cortisol 
concentration in samples. Coefficient of determination of the standard curve was 
accepted if r2 > 0.9.  
 
Chapter 2    69 
 
As supplied by the manufacturer, three controls (high, medium and low) were 
included in each assay to assess for intra-assay variability.  
 
 







Chapter 3: Effect of 
metformin on 11βHSD1 
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3.1 Introduction  
Metformin has been prescribed for over 50 years and continues to be the leading 
treatment for type 2 diabetes mellitus (T2DM). Until recently metformin has been the 
only oral hypoglycaemic agent to provide favourable effects on weight (Lee and 
Morley 1998), lipid profile (Robinson, et al. 1998) and provide potential 
cardiovascular risk reduction (UKPDS (1998)).  Through accumulative evidence of 
the deleterious effects of cortisol dysregulation, manipulation through inhibition of 
11βHSD1 looked set to provide a novel pathway for treatment of both T2DM and 
associated metabolic syndrome features. 
More than 40 programmes in pharmaceutical companies and universities have sought 
to develop selective inhibitors of 11βHSD1. The efficacy of such agents has proved 
disappointing. To date phase 2 trial data has been published for  six compounds for 
the treatment of T2DM (Feig et al. 2011; Freude et al. 2016; Heise et al. 2014; 
Rosenstock et al. 2010; Shah et al. 2011) (Table 1.1) and only one has shown 
significant improvement in the primary endpoint of improved glycaemic control 
(Rosenstock et al. 2010).  
As novel therapeutic agents, it is likely that 11βHSD1 inhibitors would be prescribed 
as second or third line agents in the treatment of diabetes thereby resulting in co-
prescription with an agent such as metformin. As discussed in Section 1.11.6, the 
cellular mechanism of action of metformin remains unclear but more broadly likely 
results in reduced hepatic gluconeogenesis and inhibition of the action of glucagon. 
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By inhibiting intracellular generation of de novo glucose it is hypothesised that 
metformin may reduce the substrate for the co-enzyme to 11βHSD1 with resultant 
lowering in the availability of the co-substrate NADPH suppressing the regeneration 
of cortisone to cortisone in tissue. Furthermore, the co-prescription of metformin 
may mask any additional glucose lowering potential that 11βHSD1 inhibtitors may 
provide.      
 
3.2 Hypothesis 
Metformin down regulates 11βHSD1 in obese individuals with and without T2DM, 
but to a greater extent in the former. The focal site of action is within the liver.  
 
3.3 Aim  
1. To investigate the potential effect of metformin on 11βHSD1 activity in 
obese non diabetic and diabetic individuals.  
2. To establish the tissue specific site of action. 
3. To examine the difference in effect of metformin on 11βHSD1 between obese 
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3.4 Methods 
3.4.1 Study design 
This placebo-controlled double-blinded cross over study was approved by the local 
research ethics committee (South East Scotland Research Ethics Committee). All 
subjects provided written informed consent.  
3.4.2 Subjects 
Five out of eight obese (BMI ≥ 30 kg/m2) non diabetic (OND) participants were 
studied in 1996 with study visits and data collection performed by Dr G Jones. The 
remaining 3 participants were recruited (2012-2014) using local advertisements and 
the local hospital diabetes register. An identical protocol was performed for the later 
3 participants as had been performed in 1996. Inclusion criteria was also consistent 
with the previous study and included male gender, age 18 to 70 years old, normal 
screening blood tests (full blood count, kidney, liver and thyroid function), no 
glucocorticoid use within the preceding 3 months, no other medications which may 
influence 11βHSD1 activity or cortisol concentrations (particularly opiates, 5-alpha 
reductase inhibitors, antifungal agents and regular non steroidal anti-inflammatory 
use except prophylactic aspirin) alcohol intake no more than recommended weekly 
amount and no significant change in weight (<5%) over the last 3 months. Data for 
the eight participants was pooled together for analysis.  
For the diabetic subjects inclusion criteria specified diet or tablet controlled diabetes 
(on metformin monotherapy) with HbA1c less than 86 mmol/mol (<10%) if diet 
controlled or less than 64 mmol/mol (<8%) if on metformin. Volunteers were 
randomised to receive either 2 tablets metformin (500 mg each) twice daily, or 2 
tablets placebo twice daily and additionally in the diabetic subjects a third phase of 
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two tablets gliclazide (40 mg each) twice daily. Tablets were manufactured by 
Tayside Pharmaceuticals with each set appearing identical. They additionally 
performed the randomisation ensuring equal numbers of participants started on each 
phase. Both investigators and participants were blinded from the treatment phase 
which was not decoded until completion of the study.  
 
3.4.3 Measurements 
Height, clothed weight, BMI, hip and waist circumference were measured as per 
standard operating procedure. A self standing height measurement scale was used to 
measure the participant’s height to the vertex of their head with their shoes off and 
back of heels and head against the measuring board (to 1 decimal place). Clothed 
weight was measured after an overnight fast using calibrated electronic scales. Waist 
circumference was measured mid way between the costal margin and the iliac crest 
with the participant standing. The hip circumference was measured with the 
participant in the same position but around the maximum circumference of the 
buttocks. Percentage body fat and lean body mass were measured using the mean of 
three recordings by bioelectrical impedance again after overnight fast. Blood 
pressure and pulse were recorded with the volunteer sitting or lying.  
 
3.4.4 Preparation of the stable isotope tracer (80% hydrocortisone and 
20% D4-cortisol) 
Hydrocortisone succinate powder (SoluCortef, Pharmacia NV/SA, Puurs, Belgium) 
(100 mg) was reconstituted in water for injection (50 mL) (2 mg/mL solution). 
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D4-cortisol was dissolved in pharmaceutical grade ethanol (1.4 mg/mL solution) and 
filtered in the radiopharmacy department to achieve sterility. Hydrocortisone 
succinate solution (1.5 mL) and deuterated cortisol solution (0.5 mL) were further 
diluted in 48.5 mL water for injection (total 3 mg hydrocortisone and 0.7 mg D4 
cortisol in 50 mL water). This was infused as a bolus over 5 minutes (600 mL/hr).  
For the continuous infusion, D4-cortisol solution (1.5 mL of 1.4 mg/mL solution) 
was diluted in 0.9% sodium chloride (saline) (494.3 mL) along with hydrocortisone 
succinate solution (4.2 mL of 2mg/mL solution) (total 8.4 mg hydrocortisone 
succinate and 2.1 mg D4-cortisol in 500 mL). This was infused at a rate of 82.9 
mL/hour providing 1.74 mg/hr of cortisol (labelled and unlabelled; 20:80).  
 
3.5 Clinical protocol 
3.5.1 Obese non diabetic participants 
The protocol for the 3 newly recruited OND participants was kept identical to that of 
the previously recruited 5 participants who were studied by Dr G Jones in 1996.  
Visit 1: Participants were prescribed tablets for 28 days. On day 26, participants 
attended the Clinical Research Facility, Western General Hospital at 8am having 
fasted from 10pm the night before. Cannulas (20 gauge) were inserted into veins in 
both antecubital fossae. From one of these, baseline samples were taken for 
background isotopologues, fasting glucose, insulin and HbA1c. This cannula was 
kept patent with a slow infusion of 0.9% saline and blood samples were taken at 
regular intervals throughout the study visit. Through the other cannula an intravenous 
bolus (3.7 mg at 20% labelled cortisol enrichment) followed by continuous infusion 
 
Chapter 3  76 
 
(1.74 mg/hr at 20% labelled cortisol enrichment) of D4-cortisol/hydrocortisone was 
given. Blood samples (7.5 mL tube with serum gel clotting activator) were taken at 
hourly intervals for the first three hours then every 15 minutes for the last hour. 
Serum was frozen at -40 ⁰C following collection.  
Visit 2: The participant continued on their tablets for the following two days. 
Dexamethasone (0.25 mg) was ingested by the participant at 10pm on day 27 before 
they returned fasted at 8am the following morning (day 28). Dexamethasone was 
used to suppress the HPA axis allowing specific measurement of cortisol generation 
by 11βHSD1. One cannula (20 gauge) was inserted into the antecubital fossa. This 
was kept patent with a slow infusion of 0.9% saline. A baseline plasma sample was 
taken for measurement of cortisol and cortisone. The participant was given 25 mg 
oral cortisone. Blood samples were taken every 15 minutes for 150 minutes and 
serum separated before being stored at -40⁰C.   
With a half life of 6 hours (Scheen 1996), a three day washout ensured complete 
clearance of metformin before the participant commenced the next set of tablets and 
an identical protocol was followed for the subsequent visits 3 and 4.  
 
3.5.2 Obese participants with type 2 diabetes mellitus 
In order to exclude any potential influence of glycaemic control on 11βHSD1 
activity, an additional phase involving gliclazide was included for diabetic subjects. 
To keep visits to a minimum and with the benefit of being able to measure hepatic 
11βHSD1 activity on the background of isotopic tracer, study visits were reduced to 
one per phase which incorporated components of day 1 and 2 for the OND 
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participants as above. The use of steady state D4-cortisol infusion (80% unlabelled 
hydrocortisone and 20% D4-cortisol) will provide some HPA axis suppression hence 
dexamethasone was not used in the protocol in this group.    
All ODM participants were on metformin monotherapy prior to commencement of 
the study. A three day washout period was therefore provided where no 
hypoglycaemic medication was taken before they were randomised to placebo, 
metformin and gliclazide in random order. No blood tests or intervention was 
performed until the study visit after taking the tablets for 28 days. Participants were 
asked to record capillary blood glucose readings 4 times a day for 2 days per week 
during each phase of the study.  
On day 28 participants attended the Clinical Research Facility at 8am having fasted 
from 10pm the night before. Anthropometric measurements as described above as 
were performed on their arrival.  
Cannulae (20 gauge) were inserted into veins in the antecubital fossae of each arm 
and lines kept patent with a slow infusion of 0.9% saline. Baseline samples were 
taken as above. A bolus and infusion of D4-cortisol/ cortisol were infused through 
the other cannula (as above). Blood samples were taken hourly for the first two hours 
then at the time points shown in the schematic below (Figure 3.1). At 180 mins, oral 
cortisone was administered (5mg). The dose of oral cortisone was reduced in 
comparison to the non diabetic subjects in view of more recent data showing that 
5mg was adequate to reveal differences in hepatic 11βHSD1 activity on a 
background of deuterated cortisol tracer (Stimson et al. 2011). Blood samples were 
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obtained more frequently following ingestion up until 240 minutes. All serum 
samples were frozen at -40 ⁰C until analysis.  
A three day washout period was again allowed to provide sufficient time for 
clearance of metformin and gliclazide (half life 11 hours) (Campbell, et al. 1991b) 
before commencing the next phase. The subsequent visit for the other two phases ran 































Where;    = blood sample 
 Figure 3.1 Schematic representation of clinical study visits  
Obese non diabetic (OND) (A = visit 1; B = visit 2) and obese participants with T2DM 
(ODM) (C)  
1 hrs   2 hrs  0 hrs  3 hrs  4 hrs  
D4-cortisol/cortisol bolus 
D4-cortisol/cortisol bolus 
D4-cortisol/ cortisol infusion  
1 hrs  0 hrs  2 hrs  3 hrs 4 hrs  
Oral cortisone 
(25mg) 
1 hrs  2 hrs  2.5 hrs   
Dexamethasone (0.25 
mg) taken at 10 pm the 
night before  
0 hrs  
Oral cortisone 
(5mg) 
D4-cortisol/ cortisol infusion 
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3.6 Analytical techniques 
3.6.1 Biochemistry  
Measurement of biochemical indices was performed in the biochemistry laboratory, 
Western General Hospital, Edinburgh. Plasma glucose was measured using a 
calorimetric assay and insulin by immunoassay using Abbott Architect analysers. 
HbA1c was measured by high performance liquid chromatography (HPLC) (HA8180 
analyser, Menarini Diagnostics, Berkshire, UK).  
3.6.2 Whole body 11βHSD1 activity 
Glucocorticoids (endogenous and deuterated were extracted from plasma (section 
2.6.2.1). Samples were analysed using LC-MS/MS (section 2.7). Mass transitions for 
the analytes cortisol, cortisone, D4-cortisol and D3-cortisol were as laid out in table 
2.2. Standard curves were prepared across the following ranges: cortisol 2 to 400ng, 
D4-cortisol, D3-cortisol and cortisone 1 to 200ng. Epi-cortisol (500 ng) and 
D8-cortisone (250 ng) were used as internal standard in all samples and standards. 
Standard curves were generated using the ratio of analyte peak area to internal 
standard peak area. For sample analysis, interference between D4- and D3-cortisol 
was corrected for when quantifying peak area. Analyte concentration was determined 
using the standard curves.  
3.6.3 Hepatic 11βHSD1 activity  
Cortisol concentrations following cortisone ingestion in the non diabetic individuals 
was measured using radioimmunoassay. As oral cortisone was administered on a 
background of deuterated tracer in the diabetic subjects, liquid chromatography/ 
mass spectrometry was used for analysis for the diabetic group. Both provide a 
quantification of hepatic 11βHSD 1 activity by first pass metabolism of cortisone.  
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3.6.4 Data Analysis  
Data are presented as mean ± SEM. Data was analysed using SPSS statistics (version 
21) using t-test and/or repeated measures ANOVA as indicated in the legends. Data 
was checked for normality of distribution using Kolmogorov-Smirnov test. 
Significance was taken as p<0.05. 
3.6.4.1 Whole body data analysis 
HOMA-IR was calculated as per Mathew et al.(Di Natale, et al. 2009; Matthews, et 
al. 1985)  
Equation 1: HOMA-IR 
HOMAIR =
Glucose x Insulin 
22.5  
Where glucose (mmol/L) and insulin (mU/L) 
 
Rate of appearance (Ra) of cortisol and D3-cortisol were calculated by dividing the 
rate of infusion of tracer by the corresponding tracer:tracee ratio (Stimson et al. 
2009). 
Equation 2: Ra Cortisol 
Ra Cortisol = �𝑅𝑎𝑡𝑒 𝑜𝑓 𝐷4−𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛
𝐷4−𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙/𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙
� −  𝑟𝑎𝑡𝑒 𝑜𝑓 𝑐𝑜𝑟𝑡𝑖𝑠𝑜𝑙 𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛  
 
                                     
 
Equation 3: Ra D3-cortisol 
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Cortisol and D4-cortisol clearance (L/min) were calculated by dividing their rate of 
infusion by their steady state concentration.  
 
3.6.4.2 Hepatic data analysis 
In the non diabetic subjects, the activation of cortisone to cortisol was calculated 
using area under the curve by plotting cortisol concentrations against time. For the 
diabetic subjects who had concurrent administration of intravenous tracer, Steele’s 
non steady state equation was applied (Equation 4).  
 
Equation 4: Steele’s non steady state equation   
Ra cortisol (t) = �infusion rate of D4 cortisol 
E(t)
� − �





Where t denotes time, V is volume of distribution, C(t) is total cortisol concentration at time 
(t) and E(t) is the tracer to tracee ratio (D4 cortisol/cortisol).  
 
 
Since the volume of distribution for cortisol is unknown this was taken as being 12 L 
as has been done for calculation of cortisol generation in additional studies (Andrew 
et al. 2005; Dube, et al. 2014; Dube et al. 2015b). 
 
3.7 Results  
One subject from the OND group had to be removed from the first phase of the study 
due to gastrointestinal side effects from the tablets. No data was collected from this 
individual whose data have therefore not been included in the results below. One of 
the non diabetic participants reduced the dose during the metformin phase to one 
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tablet once daily due to the development of diarrhoea. Removal of this subject’s data 
had no significant impact on analysis and has therefore been included in kinetic 
calculations.  
3.7.1 Participant characteristics 
Subjects with T2DM (n = 8) were significantly older than the non diabetic 
individuals (mean ± SD: OND participants 43.6 ± 13.0 vs ODM participants 65.8 ± 
2.3; p <0.05). HbA1c was statistically greater in individuals with T2DM. BMI was 
similar between the two groups (Table 3.1). All ODM participants were on statin 
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 Obese non diabetic 
participant                    
(n=8) 
Obese participants with 
type 2 diabetes mellitus 
(n=8) 
Age (years) 43.6 ± 13.0 65.8 ± 2.3* 
BMI (kg/m2) 37.4 ± 7.2 34.7 ± 3.1 
HbA1c (mmol/mol) 40.1 ± 5.4 48.2 ± 4.1* 
Table 3.1 Baseline characteristics of non diabetic and diabetic participants 




3.7.2 Biochemical data 
No ODM participants experienced hypoglycaemia. A trend was observed for 
variation in fasting glucose between phases in ODM participants (Table 3.2).  As 
anticipated, neither metformin nor gliclazide treatment resulted in a reduction in 
HbA1c. After 28 days, metformin did not result in a significant reduction in insulin 
resistance, as assessed by HOMAIR, in either ODM or OND. Only one participant in 
the ODM group had significant weight loss (4%) with metformin treatment. Weight, 
body mass index and fat mass remained steady in all other participants in both 
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 OND                     ODM 










    55.4 ± 2.5 52.4 ± 3.0 53.6 ± 3.6 
Insulin 
 (mU/L) 
 17.1 ± 5.1 10.6 ± 2.2  24.2 ± 9.7 24.9 ± 10.3 21.4 ± 7.5 




 4.5 ± 0.4 4.7 ± 0.6  3.5 ± 0.2 3.4 ± 0.2 3.4 ± 0.2 
 
Table 3.2 Biochemical effects of metformin and gliclazide in OND and ODM participants  
Analysis using repeated measures ANOVA * p < 0.1 Placebo vs  metformin vs gliclazide;    
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3.7.3 Rates of appearance of cortisol and D3-cortisol measured by 
tracer kinetic  
3.7.3.1 Non diabetic tracer data 
On the background of steady state D4-cortisol infusion, the dilution with both 
cortisol and D3-cortisol was greater following metformin treatment (Figure 3.2). 
Statistical comparisons were undertaken using average results during steady state 
(180-240 mins infusion). The rate of production of D3-cortisol was not normally 
distributed and data was transformed using log10 for statistical analysis. 
Clearance of both cortisol and D4-cortisol was not significantly different between the 
two phases. Rate of production of cortisol was not significantly different between 
groups. Metformin treatment did, however, significantly increase the generation of 
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 Figure 3.2 The effect of metformin treatment in OND individuals 
Data are mean ± SEM for plasma measurements taken over a 4 hour infusion of deuterated 
cortisol (D4-cortisol). Placebo (ο; open circles); metformin (▲; triangles). Cortisol 
concentrations (nmol/L) (Graph A); Enrichment of D4-cortisol with cortisol (%) (Graph B); 
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3.7.3.2 Diabetic patient tracer data 
Steady state was taken at the earlier time point of 150-180 minutes (Andrew, et al. 
2002). Metformin did not alter the clearance of cortisol or D4-cortisol. No significant 
difference was observed in the rate of appearance of endogenous cortisol but 
metformin did result in a significant increase in the generation of D3-cortisol 
compared with placebo and gliclazide treatment (Table 3.3). On a background 
infusion of D4-cortisol, the generation of D3-cortisol is specific to 11β-reductase 
activity. This result therefore implicates an increase in reductase activity by 
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Figure 3.3 The effects of metformin and gliclazide treatment in ODM participants  
Data are mean ± SEM for measurements taken over a 4 hour infusion of  D4-cortisol. 
Placebo (ο; open circles); metformin (▲; black triangles); gliclazide (   ; blue diamond). 
Cortisol concentrations (nmol/L) (Graph A); Enrichment of D4-cortisol with cortisol (%) 
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 OND  ODM 




0.23 ± 0.02 0.28 ± 0.04  0.27 ± 0.03 0.28 ± 0.03 0.34 ± 0.05 
D4-cortisol 
clearance   
(L/min)   
0.46 ± 0.02 0.61 ± 0.1  0.51 ± 0.06 0.53 ± 0.06 0.58 ± 0.08 
Ra cortisol 
(nmol/min)  




11.2 ± 1.4 12.9 ± 1.2*  14.21 ± 0.63 15.78 ± 0.58# 14.21 ± 0.54 
 
Table 3.3 Steady state tracer kinetics data OND and ODM participants 
Ra; Rate of appearance 
OND: Analysis using student’s t-test *= p<0.05 metformin vs placebo  
ODM: Analysis using repeated measures ANOVA # = p<0.01; p <0.01 placebo vs 
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3.7.4 Hepatic 11βHSD1 activity 
Using area under the curve, hepatic 11βHSD1 activity was calculated after oral 
cortisone ingestion for non diabetic subjects. Metformin treatment did not 
significantly alter the conversion rate of cortisone to cortisol (placebo 121,659.6 ± 
23,171.3 vs metformin 111,109.9 ± 1,7418.1 nmol/L x min).  
In the ODM group, Ra cortisol was calculated using Steele’s non steady state 
equation (Equation 4). No significant difference was seen for either rate of 
appearance of cortisol (placebo 89.11 ± 10.35 vs metformin 106.50 ± 11.67 vs 
gliclazide 81.28 ± 11.43 nmol/min; p=0.45) or area under the curve under the curve 
(placebo 5329.40 ± 651.19 vs metformin 6416.21 ± 685.15 vs gliclazide 4438.92 ± 
749.78 nmol/L/min; p=0.3) (Figure 3.4). By analysing the maximum rate of 
production a trend was observed for metformin to increase the rate of production of 
cortisol compared to gliclazide (maximum rate of production: placebo 127.2 ±23.5 vs 
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Figure 3.4 Rate of appearance of cortisol following oral cortisone administration in ODM group 
Data are mean ± SEM at intervals post oral cortisone ingestion (5mg). Placebo (ο; open 
circles); metformin (▲; black triangles); gliclazide (  ; blue diamond) 
 
3.7.5 Obese non diabetic versus diabetic participants 
Using steady state D3-cortisol production rate (without cortisone administration), a 
two way ANOVA was conducted to compare whole body 11βHSD1 activity between 
OND and ODM individuals and the impact of metformin treatment. The rate of 
appearance of D3-cortisol was significantly greater in ODM compared with OND 
individuals. No significant interaction was observed with metformin treatment 
(Figure 3.5).  
The rate of appearance of cortisol was not significantly different between obese 
individuals with metformin treatment with or without T2DM (Two way repeated 
measures ANOVA OND placebo 70.44 ± 17.63 vs OND metformin 79.73 ± 15.01 vs 
ODM placebo 54.42 ± 7.75 vs ODM metformin 57.89 ± 6.71 nmol/min; p = 0.21 























Time post cortisone (mins) 
 





Figure 3.5 Rate of appearance of D3-cortisol in OND and ODM participants   
OND Obese non diabetic individuals; ODM obese individuals with T2DM. Black bar: 
placebo; light grey bar metformin; dark grey bar: gliclazide treatment. 
Two way repeated measures ANOVA * p = 0.018 OND vs ODM; p = 0.765 OND vs ODM 
vs metformin treatment 
 
3.8 Discussion 
This chapter reports the investigation of the effect of metformin treatment on the 
regulation of cortisol through the action of 11βHSD1.  
For the first time we have observed increased whole body 11βHSD1 activity in obese 
men with T2DM compared with euglycaemic counterparts. No significant difference 
was observed between the two groups in rate of production of endogenous cortisol. A 
study comparing healthy lean individuals, obese euglycaemic and obese individuals 
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non diabetic and obese diabetic individuals but no difference was observed in 
11βHSD1 activity between the groups (Basu et al. 2005). This could be explained by 
higher circulating insulin concentrations in our participants compared with the study 
by Basu et al. resulting in greater availability of co-substrate.   
A study performed by Stimson et al. showed upregulated whole body 11βHSD1 
activity in obese diabetic patients compared with lean non diabetic individuals 
(Stimson et al. 2011). From this it was proposed that in euglycaemic obesity hepatic 
11βHSD1 activity is down regulated counterbalancing increased activity in 
alternative tissue such as adipose. With the addition of relative insulin deficiency as 
in T2DM, relatively increased hepatic 11βHSD causes further dysregulation resulting 
in elevated whole body cortisol regeneration.  The results from this study would be in 
keeping with this hypothesis. 
Contrary to our hypothesis, we have additionally shown that metformin treatment 
upregulates whole body 11βHSD1 activity in obese individuals both with and 
without T2DM. This effect was independent of the glucose lowering action of 
metformin as shown through the lack of effect from an additional hypoglycaemic 
agent, namely gliclazide. Metformin has long been thought to improve insulin 
sensitivity in T2DM (Section 1.11.6) although evidence for this is conflicting 
(Hällsten, et al. 2002; Hundal, et al. 1992; Hundal and Inzucchi 2003; Sirtori and 
Pasik 1994). With improved insulin sensitivity cellular glucose may increase with 
metformin treatment providing increased rather than the hypothesised decrease in co-
substrate for 11 βHSD1. Alternatively, metformin and perhaps AMPK may have a 
direct effect on 11βHSD1 transcription increasing cellular regeneration of cortisol 
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with an aim of benefiting from the catabolic effects in restoring the balance of 
ATP/AMP. 
Five out of the eight OND individuals were studied a number of years ago but it is 
reassuring that the effect of metformin on 11βHSD1 in these individuals is reflected 
similarly in the more recent data. 
In the knowledge that hepatic 11βHSD1 activity is sustained in individuals with 
T2DM (Stimson et al. 2011) and as the major site of extra adrenal cortisol production 
(Andrew et al. 2005; Stimson et al. 2009; Stimson, et al. 2007) it was hypothesised 
that the liver would underlie any elevation in whole body 11βHSD1 activity 
secondary to metformin treatment. This was suggested by the data but not confirmed. 
As a secondary aim, the study was not powered to detect difference in hepatic 
11βHSD1 activity and further studies would therefore be required to investigate this 
further.   
Dube et al. recently developed a triple tracer technique to measure hepatic 11βHSD1 
activity without the need for invasive procedures (Dube et al. 2014). No difference 
was observed in hepatic 11βHSD1 reductase activity between lean non diabetic, 
obese non diabetic individuals or obese diabetic individuals. The BMI of the obese 
group varied widely between 27 and 40 kg/m2.  
In this study we utilised the principle of first pass metabolism for the conversion of 
cortisone to cortisol by hepatic 11βHSD1. In the OND group we calculated area 
under the curve for the generation of cortisol whilst in the ODM group, with 
background D4-cortisol tracer infusion, we used Steele’s non steady equation as has 
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been performed in other similar studies (Stimson et al. 2011). With administration of 
oral cortisone and subsequent conversion to cortisol, the ratio of D4-cortisol to 
cortisol is altered disrupting the steady state balance (Stewart et al. 1999). As a result 
of a relative reduction in deuterated substrate, whole body 11βHSD1 activity appears 
to decrease. This can be overcome by titrating the infusion of D4-cortisol to 
compensate keeping kinetics in steady state. More recently Dube et al. have 
developed a triple tracer technique using oral [4-13C]cortisone for the measurement 
of reductase activity of 11βHSD1 and [9,12,12-2H3]cortisol (deuterated cortisol) for 
the measurement of cortisol extraction across liver. This is performed on a 
background infusion of (1,2,6,7-3H)cortisol (tritiated cortisol) allowing measurement 
of hepatic 11β-reductase activity using isotope dilution technique.          
The increase in 11βHSD1 activity may alternatively originate from adipose tissue. 
The use of ex-vivo adipose tissue biopsies would help investigate this further. 
Metformin does not appear to up-regulate alternative glucocorticoid metabolising 
enzymes as shown by the lack of significant increase in clearance of cortisol or 
deuterated cortisol. Measuring excreted urine metabolites in urine would additionally 
prove this.  
With the additional control phase with gliclazide treatment in the ODM participants, 
the protocol was altered to allow measurement of whole body and tissue specific 
activity of 11βHSD1 in one visit thereby reducing the total number of study visits. 
The set-up for measurement of whole body enzyme activity was identical between 
the two groups allowing a comparison to be made. This is not the case for the 
measurement of hepatic 11βHSD1 activity. For the ODM participants a smaller dose 
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of cortisone was administered which may have masked any increase in hepatic 
11βHSD1 activity with metformin treatment. In fact a trend was observed in this 
group that was not seen using the higher dose of cortisone in the OND group. 
Performing this test early in the morning, as was done with the OND group, has the 
potential to be influenced by higher circadian cortisol synthesis by the adrenal gland 
producing a false positive result. This was accounted for by administering 
dexamethasone to suppress the HPA axis. This was not performed in the ODM group 
although they had background tracer (80:20 unlabelled hydrocortisone: D4-cortisol 
mixture) at steady state before the administration of cortisone which may provide 
some adrenal suppression and additionally benefits from allowing any increased 
metabolism of cortisol by other enzymes, such as the 5α and 5β-reductase enzymes, 
to be accounted for. Overall without arteriovenous sampling and measurement of 
blood flow across the liver, the measurement of hepatic 11βHSD1 activity in this 
study is more qualitative than quantitative hence the impact of differences between 
protocols is less important with the biggest disadvantage being the inability to 




In conclusion, we have shown that metformin upregulates whole body 11βHSD1 
activity in obese diabetic and non-diabetic individuals. The site of action is likely to 
be the liver but increased participant numbers and in vitro studies would be required 
to elucidate a mechanism of action. Contradictory to our hypothesis, co-prescription 
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of metformin may enhance rather than attenuate the efficacy of 11βHSD1 inhibitors. 
The results of studies to date looking at 11βHSD1 inhibitors as novel treatment for 
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4.1 Introduction 
11βHSD1 is located within the endoplasmic reticulum. Cortisol must therefore first 
dissociate from its carrier protein and pass through the cell membrane before being 
metabolised by 11βHSD1. The findings from clinical studies of tissue specific 
dysregulation of 11βHSD1 in subcutaneous adipose of obese individuals (Paulmyer-
Lacroix, et al. 2002; Wake, et al. 2003) and in liver of both obese non diabetic (Rask 
et al. 2001; Rask et al. 2002) and diabetic individuals (Stimson et al. 2011) have 
relied on total plasma cortisol measurements, that is the measure of free plus bound 
concentrations of circulating cortisol. This assumes rapid equilibration between free 
and bound hormone and equal binding affinity and capacity of cortisol to CBG 
between subjects.   
There are several reasons why this may not hold true. Inflammation and more 
specifically the effect of neutrophil elastase is perhaps the most widely recognised 
influence affecting cortisol binding. With infection and inflammation neutrophil 
elastase is released and cleaves CBG dissociating cortisol from its binding sites. This 
results in an overall disproportionately higher free cortisol concentration (Ho, et al. 
2006). In such situations total cortisol levels can be misleading in the assessment of 
glucocorticoid status (Hamrahian, et al. 2004) and measurement of free cortisol may 
be a better prognostic marker in conditions such as sepsis (Fede, et al. 2014; Ho et al. 
2006). 
Cortisol binding is altered in the setting of more chronic inflammation as occurs with 
the metabolic syndrome. From a cohort in Spain, free cortisol concentrations 
correlated significantly with blood pressure, waist to hip ratio and HOMA-IR 
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(Fernandez-Real et al. 2002).  As well as the effect of neutrophil elastase, the binding 
site on CBG can become glycosylated causing a conformational change and as a 
result lowering binding affinity for cortisol (Chan et al. 2013). Sex and age have 
additionally been observed to influence circulating free cortisol (Purnell, et al. 2004). 
It is therefore evident that using total cortisol levels may not convey the magnitude 
of 11βHSD1 activity and perhaps free cortisol measurements would be more 
representative.  
No gold standard method exists for the measurement of free cortisol. Mathematical 
calculations have been formulated but rely on assumptions of binding protein 
availability and affinity. The two best recognised means of separating free from total 
cortisol are ultrafiltration and equilibrium dialysis. These have been compared with 
varying results (Pretorius, et al. 2011; Vogeser, et al. 2007). The choice of technique 
may be dependent on inescapable factors such as cost and time, and efficiency is 
often dependent upon the skill set of the operator. The small magnitude of free 
cortisol concentrations requires sensitive tools for detection and quantification. With 
wider availability this is now most commonly provided by LC-MS/MS (Kirchhoff, et 
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4.2 Hypothesis 
Measurement of 11βHSD1 turnover in the total pool underestimates 11βHSD1 
activity.   
 
4.3 Aim 
(a) To develop a reproducible method for the measurement of free cortisol. 
(b) To compare the rate of turnover between cortisone and cortisol by 11βHSD1 
assessed using the total and free pool.  
 
 
4.4 Method development  
Ultrafiltration and equilibrium dialysis were compared for sensitivity and 
reproducibility for the measurement of free cortisol concentrations in plasma. Plasma 
was stripped of steroid (section 2.5.3.2). Cortisol was added in increasing 
concentrations (125, 250 and 450 nmoles/L) and incubated (4 hours at 37⁰C). 
Ultrafiltration and equilibrium dialysis were performed (section 2.5.4 & 2.5.5) using 
1 mL plasma for ultrafiltration and 250 μL for equilibrium dialysis. Alteration in 
sample volume (concentration with ultrafiltration and dilution with equilibrium 
dialysis) were adjusted for calculating free cortisol concentration as outlined below.  
For equilibrium dialysis plasma (500 mL) was dialysed against PBS gelatin (250 μL) 
(Section 2.5.4). With free passage of unbound cortisol across the dialysis membrane 
and incubation in preset conditions (37 ⁰C rotated at 180 rpm for 16 hours) free 
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cortisol will distribute equally between each volumetric portion i.e. each 250 μL 
portion. Measurement of cortisol mass in the 250 μL dialysate (PBS Gelatin) was 
multiplied by the dilution factor. 
Equation 5: Adjustment of free cortisol mass for dilution by equilibrium dialysis  
𝐶𝑜𝑟𝑡𝑖𝑠𝑜𝑙 𝑚𝑎𝑠𝑠 (𝑛𝑔)  𝑥 �
 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (µ𝐿) + 𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒(µ𝐿)
𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (µ𝐿)
� 
i.e. for dialysis of 250 μL plasma against 250 μL PBS gelatin =  




And for dialysis of 1000 μL plasma against 250 μL PBS gelatin = 




The process of ultrafiltration results in filtration of all unbound cortisol through a 
membrane into a volume of filtered plasma matrix. Preliminary lab work revealed 
that this volume was variable following ultrafiltration of plasma (1mL) (Data are 
mean ± SEM filtrate volume; 150.22 ± 10.64 µL; relative standard deviation 17.35%) 
providing a mean concentration of volume of 6.66 times.    
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Figure 4.1 Free cortisol concentration using equilibrium dialysis and ultrafiltration 
across a range of total cortisol concentrations 
 
Free cortisol rose disproportionately as measured using equilibrium dialysis when 
cortisol spiked into plasma reached concentration 400 nmol/L postulated to be the 


































n = 6 
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 Intra-assay relative standard 
deviation (%) 












125 51.3 9.9 19.6 6.9 
250 
10.9 8.4 12.8 6.7 
450 9.4 10.8 12.0 5.7 
 
Table 4.1 Intra and inter-assay variability across a range of concentrations  
Intra-assay n = 6; inter-assay n = 4  





No gold standard method exists for the separation of free from bound cortisol. 
Equilibrium dialysis and ultrafiltration are the best studied in literature although 
neither appears superior to the other. The choice between these two methods in 
published studies appears to be based on cost, simplicity of assay and time involved 
rather than on measures of accuracy and precision (Barre, et al. 1985; Pretorius et al. 
2011; Vogeser, et al. 2002).  
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Our data has shown that equilibrium dialysis resulted in least variability as assessed 
by coefficient of variation both intra and inter-assay. No gold standard method 
currently exists for measurement of free cortisol in plasma to compare accuracy of 
the two methods. It is noted that equilibrium dialysis consistently produced higher 
free cortisol concentrations than ultrafiltration as has been seen in published data 
(Vogeser et al. 2007). It is recognised that volume dilution alters protein-ligand 
equilibrium in a sample which may explain this (Geiseler and Ritter 1984).  The 
above experiments used a ratio of plasma sample to filtrate of 2 to 1. The equilibrium 
dialysis units have a maximum capacity of 1000 µL sample against a fixed dialysate 
volume of 250 µL. Utilizing this sample to dialysate volume ratio of 4 to 1 may 
therefore cause least disruption of the existing equilibrium between free and bound 
cortisol when separating out the free cortisol pool.   
With reduced variability both inter and intra-assay, equilibrium dialysis was utilized 
in further experiments following optimization of sample volume.   
4.4.2 Optimisation of sample volume for equilibriation dialysis 
The optimum sample volume dialysed against a fixed volume of dialysate (250μL 
PBS gelatin) was investigated. Plasma obtained from the Scottish Blood Transfusion 
Service was dialysed in increasing volumes (250, 500, 750 and 1000 μL) against 250 
μL PBS Gelatin. A 4:1 plasma to dialysate ratio displayed  lowest variability 
between samples (Figure 4.1). Higher free cortisol concentrations were observed 
with a sample to dialysate ratio of 1 to 1 postulated to be the result of disruption of 
the equilibrium between free and bound ligand. 
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Figure 4.1 Variation in free cortisol concentration in response to increasing plasma sample 
volume   
Data are mean ± SEM n= 4 
 
  
4.4.2.1 Use with cortisol tracer 
Before using this method for the analysis of plasma samples from clinical studies, the 
reproducibility for the measurement of free deuterated cortisol was tested. The same 
protocol was therefore performed using stripped plasma (section 2.4.4.2) spiked with 
D4-cortisol. Plasma was incubated with D4-cortisol (450 nM for 4 hours at 37⁰C). 
Plasma (1000 μL) was then dialysed against PBS gelatine (250 μL) for 16 hours. The 
dialysate was extracted (section 2.6) before analysis using LC-MS/MS (section 2.7). 
Reproducibility was acceptable with an intra-assay coefficient of variation 2.6% 
(SEM 0.08, n = 6). Mean percentage free cortisol (free/total x 100) approximated that 
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4.4.3 Limit of detection and limit of quantification 
The sensitivity of LC:MS/MS for measurement of free deuterated cortisol was 
investigated.   
Stripped plasma was spiked with increasing concentrations of cortisol and 
D4-cortisol. Samples (1 mL) were dialysed and extracted as above. Samples were 
run using the LCMS method previously described (section 2.7).  
The limit of detection was quantified as the lowest concentration to produce a mean 
signal to noise ratio of greater than or equal to three. The limit of quantification was 
taken as the lowest concentration which was reproducible with a coefficient of 
variation of less than 20% (Armbruster and Pry 2008). 
The limit of detection for cortisol, D4-cortisol and D3-cortisol was 0.2 ng on column 
with a limit of quantification for the same of 0.5 ng on column. This meant that a 9 
mL plasma sample would be required to accurately measure cortisol and its isotopes 
under conditions previously utilized for clinical in vivo studies.  
 
4.5 Cortisol turnover in the free pool 
A study undertaken within our department by Stimson et al. (Stimson et al. 2014) 
showed acute perturbation in 11βHSD1 activity through altered diet composition. 
Whether this alteration would be reflected through assessment of the free pool was 
unknown.  
In summary the study enrolled eight healthy normal weight men aged 18 to 70 years 
who were randomised in a single blinded cross over study. Deuterated cortisol 
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(0.35 mg per hour following a bolus of 0.7 mg) was infused for 180 minutes 
achieving steady state in plasma. After 210 minutes, participants received an 
isocaloric liquid meal composed of carbohydrate, protein or fat or a low calorie 
placebo drink. Plasma samples were taken for measurement of cortisol, D4 cortisol 
and its metabolites. From this 11βHSD1 activity was calculated as has been 
described in section 3.6.  
4.5.1 Original study results 
Steady state total cortisol concentrations in all participants and across all diets were 
similar. The high protein meal led to greater endogenous cortisol production whereas 
a high carbohydrate meal increased whole body 11βHSD1 activity, as shown by an 
increased rate of production of D3-cortisol. A high fat meal had some effect on 
increasing endogenous cortisol production but had no significant effect on 11βHSD1 
activity. 
4.5.2 Methods 
To satisfy the limits of quantification, a 9 mL sample was required. Due to residual 
sample availability, samples had to be pooled together (Table 4.2). This provided 4 
pre steady state samples, 8 steady state samples and 3 subjects with samples across 3 
diets from placebo, high carbohydrate diet and high protein diet (9 samples). Pre 
steady state samples were included to investigate whether equilibrium of D4- and 
D3-cortisol occurred at an earlier time point in the free compared with the total pool.   
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 Time No. samples 
Pre steady state 60 – 120 mins 4 samples 
(8 subjects pooled together in duplicate) 
Steady state 180 - 210 mins 8 samples 
(8 individual subjects) 
Isocaloric meal 210 – 390 mins 9 samples 
3 subjects with samples across 3 meals 
(carbohydrate, protein and placebo) 
 
Table 4.2 Plasma samples pooled together from clinical study  
 
Plasma was vortex mixed before being dialysed (1 mL aliquot dialysed against 250 
μL PBS Gelatin) (section 2.5.4). Dialysates were drawn together in a glass tube 
before being mixed and extracted (as per section 2.6.2.1).  
Rather than comparing the results of free isotopolouges to original published data 
which was analysed using a different platform, a non dialysed sample of plasma (1 
mL) was simultaneously extracted and analysed alongside.   
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Analytes were reconsitituted in mobile phase (100 μL) before being analysed using 
LC-MS/MS (section 2.7). Standard curves were generated to quantify cortisol, D4-
cortisol and D3-cortisol (range 0.25 to 20 ng) using internal standard (epi-cortisol 
6.25 ng).   
The rate of appearance of cortisol and D3-cortisol were calculated as described in 
section 3.6 and as had been performed in the original study.  
 
4.5.3 Results 
Pre steady state samples showed that equilibrium had been reached (time t+ 60-120 
minutes) between the free and total pool as shown by very similar rates of production 
of cortisol and D3-cortisol (Ra cortisol free pool vs total pool; 70.0 ± 12.9 vs 66.9 ± 
12.5 nmol/min: Ra D3-cortisol free pool vs total pool; 14.3 ± 0.5 vs 14.3 ± 0.5 
nmol/min respectively) (Figure 4.2). During steady state there was no difference in 
rate of production of cortisol or D3-cortisol as assessed using the free and total pools 
(Ra cortisol free pool vs total pool, 59.0 ± 7.2 vs 54.9 ± 6.6 nmol/min; Ra D3-
cortisol free pool vs total pool, 20.1 ± 1.1 vs 19.4 ± 1.0 nmol/min respectively). 
 
 




Figure 4.2  Rate of appearance of cortisol and D3-cortisol in free and total plasma pool 
 (a) pre steady state (60 – 120 mins) and (b) during steady state (time t+ 180 – 210 mins). 
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4.5.3.1 Turnover within the free pool 
As can be seen across the time course below acute perturbation of both endogenous 
cortisol and D3-cortisol was reflected to a similar degree in the free compared with 
the total pool (Figure 4.3). With the small sample size (n = 3) in each group, kinetic 



















Figure 4.3 Tracer to tracee ratios in free and total pool 
(a) Placebo (b) High protein and (c) High carbohydrate meal.  
Tracer to tracee ratio (TTR) D4-cortisol: cortisol: total pool; dashed black line: free pool; 
solid black line 
Tracer to tracee ratio D4-cortisol: D3-cortisol: total pool; dashed grey line: free pool; solid 
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4.5.4 Discussion 
In this chapter we have developed a method for separating free from bound cortisol 
and used this to compare turnover by 11βHSD1 in the free compared with total 
plasma pool. Using samples from a previous clinical study we have shown that 
turnover between cortisol and cortisone is reflected similarly in the total compared 
with the free plasma pool. Clinical studies to date have therefore not underestimated 
11βHSD1 activity.  
We observed greater precision with equilibrum dialysis compared with ultrafiltration. 
As discussed above comparative studies have found little difference in free cortisol 
measurements between these two techniques and decision of superiority has been 
based on practical considerations such as cost, ease and time of assay. Equilibrium 
dialysis has been used in clinical studies to measure free cortisol in the setting of 
sepsis (Ho et al. 2006), alterations across gestation in pregnancy (Clerico, et al. 
1980), and in the assessment of the HPA axis (Vogeser et al. 2002). With no gold 
standard method and little data on normal reference ranges it is difficult to evaluate 
accuracy of each method. 
Both techniques lead to unavoidable alteration in volume from the initial sample 
resulting in the need for an additional corrective calculation when working out the 
final concentration. Ultrafiltration results in a concentration of sample volume whilst 
equilibrium dialysis leads to dilution. The use of a small molecule with a low binding 
affinity could be used as an internal standard eliminating the need for volume 
measurement and adjustment. Radiolabelled glucose (14C glucose) has previously 
been utilised (Adachi, et al. 1991; Hammond, et al. 1980).   
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The samples used in this study were collected 3 years previously and had been stored 
at -80⁰C since then. Endogenous glucocorticoids are stable when stored in freezing 
conditions and show little variability in concentrations with repeated freezing and 
thawing (Kley and Rick 1984). The rate of appearance of cortisol and D3-cortisol at 
steady state in the total pool in this study was compared with those from the original 
study. The Ra D3-cortisol, which utilises the ratio of D4-cortisol to D3-cortisol, was 
very similar (mean ± SEM; original study 15.6 ± 1.4 nmol/min vs this study 19.4 ± 
1.0 nmol/min) whilst the Ra cortisol, which utilises the ratio D4-cortisol to cortisol 
showed a greater discrepancy between the original and this study (original study 36.1 
± 7.3 nmol/min vs this study 54.9 ± 6.6 nmol/min). This provides additional 
reassurance of the stability of deuterated cortisol in freezing conditions.  
The binding and dissociation of cortisol to circulating proteins is a dynamic process 
which in vivo establishes equilibrium. It is possible that at sites of inflammation 
where maximal cortisol is required dissociation from CBG occurs to a greater extent 
than in the body as a whole. As discussed in Chapter 1, binding affinity of cortisol to 
CBG is altered with changes in pH, increased temperature and proteases. Plasma 
samples used in this study were from healthy volunteers reducing the potential 
impact of circulating inflammatory cytokines on CBG binding affinity. Samples were 
maintained at 37 ⁰C during equilibrium dialysis reducing disruption of ligand to 
protein equilibrium. 
Through the use of plasma samples from pre-steady state tracer infusion, we have 
shown that cortisol equilibrates rapidly between the free and bound plasma pool. 
This was further confirmed with similar tracer to tracee ratios following acute 
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perturbation. Due to the low concentration of free deuterated cortisol and the 
sensitivity of LC-MS/MS, large plasma volumes were required. This meant multiple 
samples from different time points were required to be pooled together.  
It would be of interest to compare the rate of appearance of cortisol and D3-cortisol 
in the free and total pool in obesity associated with a low-grade inflammatory state. 
 
4.6 Conclusion  
In conclusion through the use of equilibrium dialysis and measurement of turnover 
between cortisone and cortisol by 11βHSD1 in the free pool, clinical studies to date 
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5.1 Introduction 
Early studies showing an inverse relationship between measures of central adiposity 
and fasting cortisol concentrations recognized altered glucocorticoid metabolism 
with increasing central obesity (Marin et al. 1992). With isolation and 
characterization of the cortisol regenerating enzyme 11βHSD1 (Agarwal, et al. 
1989), in vivo studies began to dissect tissue specific dysregulation in relation to 
obesity and the metabolic syndrome.  
In obesity increased cortisol regeneration by 11βHSD1 has been observed in adipose 
tissue (Rask et al. 2001; Rask et al. 2002; Sandeep et al. 2005; Stimson et al. 2009). 
Hepatic 11βHSD1 activity is correspondingly down-regulated with euglycaemic 
obesity  but is sustained in the presence of T2DM postulated to be the result of 
insulin deficiency (Stimson et al. 2011). The latter finding has not been consistent 
(Basu et al. 2005; Dube et al. 2015a).  
The effects of insulin on whole body and tissue 11βHSD1 activity have been 
variable. A study comparing the effects of hyperinsulinaemia between lean and obese 
individuals showed acute downregulation of adipose 11βHSD1 activity in lean but 
not obese individuals postulated to be the result of altered co-enzyme and co-
substrate (Sandeep et al. 2005). In healthy male individuals hyperinsulinaemia 
resulted in upregulated 11βHSD1 reductase activity in whole body and adipose tissue 
(Wake et al. 2006). No in vivo data exists for the direct effect of insulin on 
hepatocytes but can be inferred in individuals with T2DM (Stimson et al. 2011) and 
with alteration in diet composition (Stimson et al. 2014). Hepatocytes cultured with 
high insulin concentrations display a reduction in 11βHSD1 mRNA but with little 
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effect on enzyme activity as measured in the reductase direction (Jamieson et al. 
1995). Different tissues may respond differently to hyperinsulinaemia and evidence 
exists from in vivo studies that the effect of insulin may relate to acute versus chronic 
changes (Stimson et al. 2007; Stimson et al. 2014).  
A main hypothesis has been that 11βHSD1 acts exclusively as a reductase enzyme in 
vivo and as such assessment of 11βHSD1 activity and interpretation of altered 
mRNA and protein levels has focused on the consequences of local cortisol 
regeneration from cortisone. However, a recent study undertaken within the 
department using D2-cortisone tracer to measure dehydrogenase activity as well as 
the D4-cortisol tracer to measure reductase activity has shown bidirectional activity 
by 11βHSD1 in vivo with a ratio of reductase to dehydrogenase activity of 1:1.3 in 
adipose tissue and 1:1 in skeletal muscle (Hughes et al. 2012).  If confirmed, this 
suggests that variations in 11βHSD1 expression and alterations in 11 β-reductase 
activity, may not have the predicted effect on intracellular cortisol levels since there 
may be simultaneous up-regulation of 11 β-dehydrogenase activity. This could 
explain the disappointing effects of some 11βHSD1 inhibitors on glycaemic control 
in T2DM, if there were inhibition of both dehydrogenase and reductase activities. 
Moreover, since reductase activity can be abolished in favour of persisting 
dehydrogenase activity by the removal of H6PDH (Lavery et al. 2006) it may be that 
variations in cofactor availability control the balance between dehydrogenase and 
reductase activities of 11βHSD1 in vivo in humans and this mediates the context-
dependent effects of insulin on enzyme activity.  
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5.2 Hypothesis 
11βHSD1 acts as a bidirectional enzyme catalyzing reductase and dehydrogenase 
reactions with directionality in favour of reductase activity in obese individuals 
which is further enhanced with hyperinsulinaemia 
 
5.3 Aims 
1. Confirm bidirectional activity of 11βHSD1in intact cells using deuterated 
tracer in vitro 
2. Quantify directional activity using deuterated cortisol and cortisone tracers in 
vitro 
3. Quantify directional activity of 11βHSD1 in whole body and across tissue in 
lean and obese individuals using deuterated cortisol and cortisone tracers. 
4. Assess the effect of altered cellular environment with hyperinsulinaemia on 
directional activity of 11βHSD1 in whole body and across tissue in lean and 
obese individuals using deuterated cortisol and cortisone tracers. 
 
5.4 Directionality of 11βHSD1 in vitro 
5.4.1 Methods 
HEK-293 cells stably transfected with 11βHSD1 (HEK 293-11βHSD1) (Section 
2.4.3) were thawed rapidly and cultured in cell growth medium (section 2.4.2.1) in 
culture flasks pre-treated with Poly-D-lysine under standard tissue culture conditions 
(section 2.4.4). Cells were split every third day once confluent. For experimental use 
cells (1x106) were seeded onto 12 well plates pre-coated with poly-D-lysine and 
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incubated for 24 hours in growth medium. PBS was used to wash the cells before 
replacing the medium for stripped steroid medium (section 2.4.2.2) for 24 hours.  
Stock solutions of deuterated cortisol (D4 cortisol) (1 mg/mL) and unlabelled 
cortisone (1 mg/mL) were diluted in serum free medium (medium for assay 2.4.2.3 ) 
to achieve a concentration of 500 nmol/L.  After thorough mixing, 1 mL of medium 
with either D4-cortisol or cortisone was aliquoted into the desired number of wells 
allowing experiments to be performed in triplicate. Simultaneous control 
experiments were performed with the omission of cells.  At pre-determined time 
points (6, 12, 24 and 48 hours) the medium was harvested and transferred into a glass 
bijou.  Samples were frozen at -20 ⁰C until analysis was performed.  
Glucocorticoid extraction from the medium was performed and standards generated 
as described previously (section 2.6.1). Standards and samples were analysed by 
LC-MS/MS (section 2.7). Standard curves were generated (section 2.6.1) from which 
concentrations of deuterated and endogenous glucocorticoids in the samples could be 
calculated.   
5.4.2 Results 
Analysis of control samples using LC-MS/MS found detectable naturally occurring 
isotopologues of cortisol with mass to charge ratio equivalent to that of D4- and D3-
cortisol. The mean of these was subtracted from the mean mass of the experimental 
samples at each time point. Data are reported as mean ± SEM.  
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When incubated with cortisone, HEK 293-11βHSD1 cells generated cortisol 




Figure 5.1 Conversion of cortisone to cortisol by 11βHSD1 in HEK293-11βHSD1 cells 
Black circles: cortisone; Grey triangle: Cortisol. Mean data ± SEM. n=9  
  
Incubation of HEK 293-11βHSD1 cells with D4-cortisol generated D3-cortisone 
after 6 hours. D4-cortisol mass showed little variation in the first 6 hours despite this 
rapid increase in generation of D3-cortisol. With a natural abundance of 0.01%, the 
potential for spontaneous generation of D4-cortisol or D3-cortisol is negligible. It is 
therefore possible that the measured mass of D4-cortisol at time point 0 was 
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top of the standard curve range (range 2 ng/ml to 250 ng/ml (Section 2.6.1)) which 
may explain this lower than anticipated result.  
This increase in D3-cortisol was not did not correspond Generation of D3-cortisol 
peaked by 12 hours and remained steady for the subsequent 36 hours. Production of 
D3-cortisol rose steadily over the entire 48 hours. D4-cortisol mass declined between 
12 and 48 hours. 
 
Figure 5.2 Dehydrogenase and  reductase activity by 11βHSD1 following incubation of HEK293-
11βHSD1  cells with D4-cortisol 
Black diamonds: D4-cortisol; grey triangle: D3-cortisone; grey square: D3-cortisol. Mean 
data ± SEM. n=9   
 
5.4.3 Discussion 
Our work has shown that 11βHSD1 can act both as a reductase and dehydrogenase 
enzyme as previously observed in vitro (Lakshmi and Monder 1988) and in vivo 
(Hughes et al. 2012). Having been stably transfected with 11βHSD1, HEK293-
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generation before adequate substrate is available for reduction to D3-cortisol. As 
such this appeared to result in a lag time before the regeneration of cortisol in the 
form of D3-cortisol.   
Application of results from in vitro studies to human physiology can be limited due 
to the false fixed environment in which in vitro studies are performed. It is therefore 
of interest how alteration in cellular metabolism may affect enzyme directionality 
and overall cellular balance between active and inactive glucocorticoids.  
 
5.5 Cortisol-cortisone recycling in vivo 
 
5.5.1 Methods 
5.5.1.1 Study design  
This random-order two-phase crossover single-blinded study was approved by the 
local research ethics committee (South East Scotland Research Ethics Committee). 
All subjects provided written informed consent.  
5.5.1.2 Subjects 
Ten lean (BMI 20-25kg/m2) and ten obese (BMI >30kg/m2) healthy male volunteers 
were recruited. Each participant attended for a screening visit to ensure inclusion 
criteria were met (age between 20 to 70 years, no significant systemic illness or 
history of diabetes mellitus, no glucocorticoid use in the preceding 3 months, alcohol 
intake less than 21 units per week, normal screening bloods (full blood count, 
random glucose, kidney, liver and thyroid function) and no regular anticoagulation 
use).  
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5.5.1.3 Measurements  
Participants attended the Clinical Research Facility, Royal Infirmary Edinburgh at 
8am having fasted from 10pm the night before. Measurements were taken of clothed 
height, weight, waist and hip circumference as well as percentage body fat (as per 
section 3.4.3).   
5.5.1.4 Preparation of stable isotope tracer 
5.5.1.4.1 D4-cortisol 
Deuterated cortisol (D4-cortisol) was diluted in pharmaceutical grade ethanol (90%) 
(1.4 mg/mL) and filtered to achieve sterility. Further dilution (1.5 mL of 1.4 mg/mL 
solution) in 0.9% saline (19.5 mL) was undertaken before a bolus (total dose 1.4 mg) 
was infused over 5 minutes. After this time a continuous infusion (3.4 mL of 1.4 
mg/mL stock solution in 325 mL 0.9% saline) was infused over the study period of 5 
hours (total dose 3.56 mg).  
5.5.1.4.2 D2-cortisone 
Stock solution was made by diluting deuterated cortisone (D2-cortisone) in 
pharmaceutical grade ethanol (90%) (230 µg/mL). For the bolus, 0.4 mL was diluted 
in 18.4 mL 0.9% saline (total dose 76 µg) and infused over 5 minutes. For the 
continuous infusion 2.4 mL of 230 µg/mL stock solution was diluted in 247.6 mL 
0.9% saline. Work within our department has shown that primed infusion of 
D2-cortisone rapidly reaches steady state (Hughes et al. 2012) hence this was 
commenced at time+ 60 minutes. Total dose infused over 4 hours was 421.21 µg.  
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5.5.1.4.3 Preparation of insulin infusion  
Actrapid (0.3 mL of 100 units/mL) was diluted in 0.9% saline (100 mL) creating a 
concentration of 0.3 units/mL. Rate of infusion was 35  mU/m2/h based on surface 
area as calculated below (Du and Du 1916).  
Equation 6: Calculation of body surface area 




5.5.2 Clinical protocol 
A cannula (20-gauge) was inserted into a vein in the antecubital fossa. This was used 
for infusion of dueterated cortisol (D4-cortisol) and cortisone (D2 cortisone). Three 
further retrograde cannulas were inserted to measure 11βHSD1 reductase and 
dehydrogenase activity across whole body, forearm muscle and abdominal 
subcutaneous adipose tissue (Figure 5.3).  
One cannula (20-gauge) was inserted into a vein on the dorsum of the hand which 
was placed in a heated box (controlled at 60⁰C; manufactured in house) for 5 minutes 
prior to sampling in order to arterialize the blood (oxygen saturation confirmed as 
> 98%). This provides a measure of glucocorticoid concentrations in whole body and 
entering tissue without the need for more invasive arterial cannulation. This 
technique has been used in several other studies (Dube et al. 2015b; Stimson et al. 
2009; Stimson et al. 2011). The second (20-gauge) was placed in a branch of the 
cubital vein near the antecubital fosse on the opposite side. Blood gas measurement 
ensured oxygen saturation < 40%. An inflatable cuff was placed at the wrist and 
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inflated to 200 mmHg for 2 minutes prior to sampling to minimize contamination of 
venous blood from the hand. The third cannula (18-guage) was placed in a branch of 
the superficial epigastric vein in subcutaneous adipose tissue of the abdominal wall. 
This was inserted under guidance of a filtered red light (section 2.2.2). The tip of this 
cannula was kept above the inguinal ligament to prevent contamination from venous 
drainage from the leg. Oxygen saturation was confirmed as being > 85%. These 
cannulas were kept patent with a slow infusion of 0.9% saline. Infusion was stopped 
and dead space withdrawn before blood samples were obtained. Samples were taken 
at the time points as outlined in  below. 
  
Figure 5.3 Study set-up 
 
5.5.2.1 Blood flow measurement  
At sampling time points blood flow was measured through forearm muscle and 
abdominal subcutaneous adipose tissue.  For forearm muscle blood flow venous 
occlusion plethsymography was utilized (section 2.2.2.4) (Benjamin, et al. 1995). A 
strain gauge was applied across the mid forearm and blood flow obstructed at the 
wrist using a cuff inflated to 200 mmHg. Intermittent obstruction then release of 
Key: 
     Cannula for infusion 
         Cannula for sampling 
        Sphgmomanometer cuff 
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venous outflow above the forearm creates dilation of the arm which is detected by 
the strain gauge and corresponds to arterial blood flow rate.  
Xenon133 (section 2.3.1.7.1) was used for blood flow measurement through 
abdominal subcutaneous adipose tissue (Larsen, et al. 1966). Following dilution, a 
dose of 2MBq was drawn up (section 2.2.2.5.1) and injected lateral to the umbilicus. 
A gamma counter was secured in place at the site of injection and was set to measure 









Figure 5.4 Schematic of protocol  
  = sampling point and Q = blood flow measurement 
 
Bolus and infusion D2-cortisone 
Q Q                     Q                      Q   Q       Q 
Bolus and infusion D4-cortisol 





3hr 4hr 5hr 0hr Time 
(Insulin + dextrose) OR 
saline infusion 
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5.5.2.2 Hyperinsulinaemic euglycaemic clamp 
At one visit subjects received a hyperinsulinaemic euglycaemic clamp and at the 
other an infusion of saline as placebo. Patients were randomized (performed by 
research nurse at Clinical Research Facility, Royal Infirmary, Edinburgh) and 
blinded to which they were receiving. Capillary glucose was recorded every 5 
minutes for the duration of the infusion (insulin or placebo). A dextrose infusion 
(10%) was run alongside the insulin infusion and the rate adjusted to maintain 
capillary glucose between 4.5 and 5.5 mmol/L. 
5.5.3 Analytical techniques 
5.5.3.1  Whole body and tissue specific 11βHSD1 activity 
Glucocorticoids (endogenous and deuterated) were extracted from plasma (section 
2.6.2.1).  Samples were analysed using LC-MS/MS (section 2.7). Mass transitions of 
the analytes were as per Table 2.2. Standard curves were prepared across the 
following ranges: cortisol 2 to 400 ng; D4-cortisol 1 to 200ng; D3-cortisol 1 to 200 
ng and D2-cortisone 0.5 to 100 ng. Epi-cortisol (500 ng) and D8-cortisone (250 ng) 
were used as internal standard in all samples and standards. Standard curves were 
generated using the ratio of analyte peak area to internal standard peak area. 
Interference between D4- and D3-cortisol in the analysis of samples was corrected 
for when quantifying peak areas. Standard curves were used to quantify analyte 
concentrations.   
An enrichment curve of increasing D4-cortisol against a background of steady 
concentration of D3-cortisol showed lower than anticipated ratios of D4-cortisol: D3-
cortisol peak area implicating unequal ionization of these analytes when co-existing 
in samples. Interference of one analyte to another was calculating in samples of 
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known concentrations of each (D4-cortisol and D3-cortisol) allowing tracer to tracee 
ratio in plasma samples to be adjusted accordingly.   
5.5.3.2 Tracer kinetics 
Rate of appearance of cortisol and cortisone as a measure of reductase and 
dehydrogenase activity by 11βHSD1 were measured as per Equation 7 and 8 below. 
Rate of appearance of D3-cortisol were calculated as described previously (Section 
3.6.2).  
 
Equation 7: Ra cortisol 
Ra cortisol (nmoll/min) = 
       (D4-cortisol/cortisol)   
rate D4-cortisol infusion 
   
Equation 8: Ra cortisone 
Ra cortisone (nmol/min) = rate of D2-cortisone infusion





Clearance of D4-cortisol was calculated by dividing the rate of infusion by its steady 
state concentration (L/min).  
The rate of appearance of cortisol, D3-cortisol and cortisone across tissues was 
calculated using arteriovenous differences in tracer: tracee ratio whilst factoring in 
blood flow rate through the tissue as outlined below.  
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Equation 9: Cortisol release across tissue 
Ra cortisol across tissue (nmol/l00 g tissue/min) = 
BF x [cortisol] artery x   D4-cortisol/cortisolartery
  D4-cortisol/ cortisolvein 
 – (BF x [cortisol]artery) 
 
 
Equation 10: D3-cortisol release across tissue 
Ra D3-cortisol across tissue (nmol/l00 g tissue/min) = 
BF x [D3-cortisol] artery x  D4-cortisol/D3-cortisolartery
    D4-cortisol/ D3-cortisolvein 
 – (BF x [D3-cortisol]artery) 
 
 
Equation 11: Cortisone release across tissue 
Ra cortisone across tissue (nmol/l00 g tissue/min) = 
BF x [cortisone] artery x  D2-cortisone/ cortisoneartery
  D2-cortisone/ cortisonevein 
 – (BF x [cortisone]artery) 
 
Where BF: blood flow (mL/min/100 g tissue) and [ ] denotes concentration.  
 
5.5.4 Statistics 
Data was analysed using SPSS statistics 23 (IBM). Steady state data was assessed 
between time+ 120 to 180 minutes. Difference between groups and phases was 
determined using a student’s t-test.  The influence of hyperinsulinaemia on 
glucocorticoid metabolism in whole body and muscle was determined using repeated 
measures analysis of variance (ANOVA) across the period +180 to +300 minutes. 
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Due to failure in plasma sampling from the intra-adipose cannula in the abdominal 
wall data for some individuals was incomplete. Individual missing data points were 
filled by taking the mean of the two surrounding values. Where few data points were 
available, missing data was left incomplete. For analysis of data from adipose tissue 
repeated measures ANOVA for the placebo/ insulin phase were limited to time + 
270-300 minutes to maximize data for analysis.  
All data are reported as mean ± SEM unless otherwise stated. 
5.5.5 Results  
5.5.5.1 Participant characteristics 
One participant in the obese group was found to have developed a high fasting 
glucose level at his first visit. Data from this visit was excluded and his participation 
in the study was terminated. Ten lean (BMI 23.77 ± 0.38 kg/m2) and ten obese (BMI 
32.92 kg/m2 ± 0.86 (p<0.001)) healthy male volunteers attended two study visits. 
Participants were matched for age (lean participants 50 ± 3.28 years; obese 
participants 50.5 ± 3.28 years). Obese participants had a significantly higher 
percentage body fat mass (obese 29.88 ± 1.41% vs lean 20.54 ± 1.94%; p = 0.001). 
Obese individuals had lower baseline plasma cortisol (lean 222.6 ± 47.2 vs obese 
187.6 ± 41.3 nmol/L; p=0.58) and cortisone (lean 45.7 ± 6.7 versus obese individuals 
39.4 ± 8.2 nmol/L; p=0.56).  
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5.5.5.2 Steady state glucocorticoid kinetics before insulin/placebo 
infusion  
5.5.5.2.1 Whole body glucocorticoid metabolism in steady state  
During infusions, arterialised plasma cortisol and cortisone concentrations were 
similar between groups (lean vs obese individuals) and between visits (placebo vs 
hyperinsulinaemia) (Figure 5.5).  
Arterialised D4-cortisol concentrations and enrichment with D3-cortisol were in 
steady state by 120 minutes. D2-cortisone and enrichment with cortisone had 
achieved steady state by the same time. The ratio of D4-cortisol: D3-cortisol (tracer: 
tracee ratio) appeared to be lower in arterialised blood in obese than lean individuals 
(Figure 5.6). This may be the result of a larger volume of distribution of tracer in 
obese individuals although this was not similarly reflected with the tracer D2-









                                                                                                                                                   




Figure 5.5 Concentration of cortisol and cortisone in arterialised blood 
Where (a) cortisol; (b) cortisone. Blue solid line: obese placebo; blue broken line: obese 
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Figure 5.6 Arterialised tracer to tracee ratios 
Arterialised tracer to tracee ratios for (a) D4-cortisol/ cortisol (b) D4-cortisol/ D3-cortisol 
and (c) D2-cortisone/ cortisone. Blue solid line: obese placebo; blue broken line: obese 
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Across whole body, rates of appearance of cortisol, D3-cortisol and cortisone did not 
differ significantly within each group between the two visits at steady state (pre-
insulin vs pre-placebo infusion). No significant difference was observed in 
generation of cortisol, D3-cortisol or cortisone across whole body between lean and 
obese individuals (Table 5.1). 
The clearance of D4-cortisol did not differ between groups (steady state: lean 0.47 ± 
0.07 vs obese 0.54 ± 0.06 L/min; p = 0.49). 
 
Table 5.1 Steady state rates of appearance in whole body   
Rates of appearance of cortisol, D3-cortisol and cortisone in whole body (nmol/min). Data 




5.5.5.2.2 Adipose tissue and skeletal muscle glucocorticoid metabolism in 
steady state  
Blood flow through adipose tissue was significantly greater in obese compared with 
lean individuals during placebo phase (Figure 5.8) (p<0.05). Blood flow rate was 
similar through skeletal muscle in lean and obese individuals (Figure 5.9). 
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Arteriovenous differences in cortisol, cortisone and tracer: tracee ratios are shown in 
Figure 5.11 and Figure 5.12. 
The resulting kinetic calculations for steady state are shown in Table 5.2. Across 
adipose tissue, the rate of appearance of cortisol, D3-cortisol and cortisone was 
different from zero in obese individuals only. Across skeletal muscle the rate of 
appearance of cortisol and cortisone was different from zero in lean individuals only.   
At steady state, no significant difference was observed between the rate of 
appearance of cortisol, D3-cortisol or cortisone between phases (pre-insulin and pre-
placebo) in skeletal muscle or adipose tissue. Comparison between groups at steady 
state was therefore performed using data from the placebo phase using student’s t-
test. Lean individuals displayed a significantly greater generation of cortisol in 
skeletal muscle than obese individuals (Ra cortisol; lean 20.44 ± 9.43 vs obese -









                                                                                                                                                   





Table 5.2 Rates of appearance in skeletal muscle and adipose tissue 
Rates of appearance of cortisol, D3-cortisol and cortisone in skeletal muscle and adipose 
tissue (nmol/min). Data are mean ± SEM.  
* p <0.05 for lean vs obese by independent sample t-test 




5.5.5.3  Effect of hyperinsulinaemia on glucocorticoid metabolism  
With hyperinsulinaemia, mean glucose concentrations were maintained at 
physiological concentration (time t+ 180- 300 mins; lean placebo 5.32 ± 0.17 vs lean 
insulin 4.90 ± 0.13 vs obese placebo 5.25 ± 0.14 vs obese insulin 4.92 ± 0.26 
mmol/L). Across time blood glucose concentrations were significantly higher early 
and lower later during insulin infusion compared with placebo in both lean and obese 
individuals (Figure 5.7).    
  
Ra cortisol      
(pmol/100 g tissue/ 
min) 
Ra D3-cortisol 
(pmol/100 g tissue/ 
min) 
Ra cortisone 
(pmol/100 g tissue/ 
min) 
  Placebo Insulin Placebo Insulin Placebo Insulin 
Skeletal 
muscle 












Obese -13.51 ± 
12.36* 
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Figure 5.7 Glucose excursion  
Glucose concentrations (mmol/L). Blue solid line: obese placebo; Blue broken line: obese 
insulin; Red solid line: lean placebo; Red broken line; lean insulin. Data are mean ± SEM 
 
Figure 5.8 Blood flow adipose tissue  
Blood flow as measured using Xenon133 washout. Blue solid line: obese placebo; Blue 
broken line: obese insulin; Red solid line: lean placebo; Red broken line; lean insulin. 
Data are mean ± SEM. Lean vs obese (placebo phase) using student’s t-test (p<0.05). Using 
two way repeated measured ANOVA there no significant effect of hyperinsulinaemia on 












































                                                                                                                                                   






Figure 5.9 Blood flow in skeletal muscle  
Blood flow as measured using venous occlusion plethsmography. Blue solid line: obese 
placebo; Blue broken line: obese insulin; Red solid line: lean placebo; Red broken line; 
lean insulin. Data are mean ± SEM. Two way repeated measures ANOVA; overall p = 0.04; 
interaction with: subjects p = 0.99; obese vs lean p = 0.26; placebo vs insulin p = 0.47; lean 




5.5.5.3.1 Whole body glucocorticoid kinetics during insulin infusion 
D4-cortisol clearance was not significantly altered by hyperinsulinaemia (t+ 180 – 
300 mins: lean placebo 0.47 ± 0.07 vs lean insulin 0.45 ± 0.06 L/min: p= 0.27; obese 
placebo 0.54 ± 0.06 vs obese insulin 0.56 ± 0.07 L/min: p=0.62).   
A two way repeated measures ANOVA was conducted to examine the effect of 
group and insulin treatment on the rate of appearance of cortisol, D3-cortisol and 
cortisone using absolute rates of appearance which are described in the text and in 
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by subtracting data during the placebo phase from that in the insulin phase for each 
subject (Figure 5.10).   
Across whole body the rate of appearance of D3-cortisol and cortisone increased 
somewhat in lean individuals during the hyperinsulinaemic euglycaemic clamp 
although there was no significant difference between lean and obese individuals 













                                                                                                                                                   




Figure 5.10 Placebo-corrected whole body rates of appearance of cortisol, D3-cortisol and 
cortisone during insulin infusion from t + 180 mins 
Placebo adjusted rates of appearance of (a) cortisol (b) D3-cortisol and (c) cortisone in whole 
body pre- and following hyperinsulinaemia commenced at t = 180 mins. 
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Table 5.3 Mean rates of appearance (Ra) of cortisol, D3-cortisol and cortisone in whole body 
during saline placebo infusion and with hyperinsulinaemia  
Ra D3-cortisol: p<0.001; lean vs obese p=0.68; placebo vs insulin p=0.026 







5.5.5.3.2 Adipose and skeletal muscle glucocorticoid kinetics during insulin 
infusion 
Cortisol and cortisone concentrations were similar between arterialised and venous 
samples across adipose tissue and skeletal muscle in both lean and obese individuals 
(Figure 5.11 and Figure 5.12).  
Statistical testing was restricted to rates of appearance after correction for blood flow 
for time+ 180-300 minutes for skeletal muscle and time+ 270-300 minutes for 
adipose tissue due to difficulties with sampling with the later. Data are presented for 
clarity as ‘placebo corrected’ in Figure 5.13 and mean rates of appearance in Table 
5.4.  
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Across adipose tissue obese individuals tended to have increased  rate of appearance 
of cortisol compared with lean individuals (Table 5.4). No significant difference was 
observed across this tissue for the rate of appearance of D3-cortisol or cortisone with 
hyperinsulinamia in either group. Additionally, no significant difference was 
observed for the rate of appearance of cortisol, D3-cortisol or cortisone across 
skeletal muscle in the lean or obese group.   
As shown by the placebo corrected rates of appearance (Figure 5.13) results were 













                                                                                                                                                   






Figure 5.11 Arterio-venous differences in cortisol across adipose tissue and skeletal muscle 
during placebo saline infusion and hyperinsulinaemic euglycaemic clamp 
Arterialised and venous concentrations (nmol/L) of cortisol across adipose tissue in (a) obese 
individuals and (b) lean individuals and across skeletal muscle in (c) obese individuals and 
(d) lean individuals.  
Placebo phase - Blue solid line: arterial concentration; Blue broken line: venous 
concentration in obese individuals. Red solid line: arterial concentration; red broken line: 
venous concentration in lean individuals.  
Hyperinsulinaemic phase – Green solid line: arterial concentration; Green broken line; 
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Figure 5.12 Arterio-venous differences in cortisone across adipose tissue and skeletal muscle 
during placebo saline infusion and hyperinsulinaemic euglycaemic clamp 
Arterialised and venous concentrations (nmol/L) of cortisone across adipose tissue in (a) 
obese individuals and (b) lean individuals and across skeletal muscle in (c) obese individuals 
and (d) lean individuals 
Placebo phase - Blue solid line: arterial concentration; Blue broken line: venous 
concentration in obese individuals. Red solid line: arterial concentration; Red broken line: 
venous concentration in lean individuals  
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Figure 5.13 Placebo-corrected rates of appearance of cortisol, D3-cortisol and cortisone in 
adipose tissue and skeletal muscle during insulin infusion from t + 180 mins 
Placebo adjusted rates of appearance of (a) cortisol (b) D3-cortisol and (c) cortisone in 
adipose tissue (right) and skeletal muscle (left) pre- and following hyperinsulinaemia 
commenced at t = 180 mins 
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Table 5.4 Mean rates of appearance (Ra) of cortisol, D3-cortisol and cortisone across adipose 
tissue  during saline placebo infusion and with hyperinsulinaemia 
Ra cortisol: p<0.01; lean vs obese p=0.62; placebo vs insulin p=0.11 
 
5.5.5.4 Tissue specific reductase: dehydrogenase activity 
The ratio of rate of appearance of D3-cortisol (Ra D3-cortisol) to rate of appearance 
of cortisone (Ra cortisone) provides a comparative measure of rate of reductase to 
dehydrogenase activity by 11βHSD1 activity across tissue. Across skeletal muscle 
during steady state (Table 5.1), the ratio of Ra D3-cortisol to Ra cortisone was 
predominantly dehydrogenase (ratio = 0.2) whilst in obese individuals it was 
predominantly reductase (ratio = 1.41). Across adipose tissue, lean individuals again 
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showed predominance of dehydrogenase activity (ratio = 0.26) with predominantly 
reducatsae activity in obese individuals (ratio = 3.26).  
 
5.5.6 Discussion 
Using deuterated tracers for the quantification of 11β-reductase and 11β-
dehydrogenase activity, we have shown similar 11βHSD1 activity in whole body 
between lean and obese individuals. This corroborates with previously published data 
(Dube et al. 2014; Sandeep et al. 2005). Across tissues, obese individuals had 
quantifiable 11β- reductase and 11β-dehydrogenase activity that was different from 
zero in subcutaneous adipose tissue but not in skeletal muscle. In lean individuals the 
appearance of cortisol and cortisone was significantly different from zero in skeletal 
muscle only. Unlike the generation of D3-cortisol, the appearance of cortisol may 
reflect increased endogenous adrenal production.rather than 11βHSD1 activity. With 
acute perturbation of the enzyme with hyperinsulinaemia, whole body 11β-reductase 
and 11β-dehydeogenase activity was increased although there was no significant 
difference between the two groups. This may reflect increases insulin sensitivity in 
lean individuals exemplifying the role of insulin in increasing 11βHSD1 activity. 
Across tissue, there was a trend for hyperinsulinaemia to increase the production of 
cortisol in obese but not lean individuals. This may reflect adrenal synthesis rather 
than 11βHSD1 activity.  It is additionally recognised that due to slow accumulation 
of D4-cortisol into tissue such as subcutaneous adipose and hence slow generation of 
D3-cortisone, 11β reductase activity may be reflected through the generation of 
cortisol rather than through the anticipated D3-cortisol production (Hughes, et al. 
2010). 
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The measurement of glucocorticoid kinetics across tissue may be influenced by 
blood flow across that tissue. Obese individuals displayed significantly lower blood 
flow rates during the placebo but not hyperinsulinaemic phase. Blood flow rates 
following an overnight fast have been reported to be around 3 mL/100g tissue/min in 
adipose tissue and 1.5 mL/100g tissue/min in skeletal muscle (Elia and Kurpad 
1993). Our study found slightly lower blood flow rates through adipose tissue yet 
slightly higher rates through skeletal muscle. It is recognised that fasting (Hagstrom-
Toft, et al. 1997; Klein, et al. 2000) and mental stress (Linde, et al. 1989) can 
increase whilst obesity (Jansson, et al. 1998) and insulin resistance (Karpe, et al. 
2002) can lower blood flow rate in tissue.  
Previous studies have shown upregulated 11β-reductase activity in adipose tissue 
with obesity (Rask et al. 2001; Stimson et al. 2009). Although we did not observe 
any significant difference in 11βHSD1 activity between lean and obese individuals, 
we have shown quantifiable reductase and dehydrogenase activity in this tissue in 
obese but not lean individuals. The significance of adipose tissue in cortisol 
generation is additionally highlighted by comparing the rate of reductase to 
dehydrogenase activity between lean and obese individuals with predominantly 
dehydrogenase activity in the former and reductase activity in the later.  
A recent study using a novel triple tracer technique also observed no significant 
difference in the rate of appearance of cortisol across subcutaneous adipose tissue in 
obese compared with lean individuals (Dube et al. 2015a). This study used 
microdialysis catheters for sampling across tissue. The smaller sample volume 
generated by this technique may impact on results especially if tracer enrichment 
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within the tissue is low or if alterations in tracer to trace ratio are of a small 
magnitude.  
Across skeletal muscle we observed production of cortisol, D3-cortisol and cortisone 
in lean individuals only. Few studies have investigated glucocoticoid kinetics across 
skeletal muscle in vivo. A study performed by Basu et al. showed in a cohort of 
obese individuals D3-cortsol production did not differ from zero both before or 
during an insulin infusion (Basu et al. 2004). A study performed within our 
department showed quantifiable rates of production cortisol, D3-cortisol and 
cortisone across forearm skeletal muscle in lean/overweight men (Hughes et al. 
2012).   
With hyperinsulinaemia only adipose tissue displayed alteration in the rate of 
appearance of glucocorticoids with a trend for increased cortisol generation in obese 
individuals. The appearance of cortisol across this tissue may reflect increased 
adrenal synthesis but could still conceivably be due to increased 11βHSD1 activity 
which is masked by the slow accumulation of D4-cortisol into the tissue as discussed 
above. Upregulation of adipose 11βHSD1 activity has been observed in a previous in 
vivo study following insulin infusion (Wake et al. 2006).  In vitro data has shown that 
insulin has no effect on availability of coenzyme H6PDH but does extend the half 
life of 11βHSD1 mRNA two fold (Balachandran et al. 2008).  By driving glucose 
into cells, insulin can increase substrate for H6PDH generating more NADPH and 
hence driving 11βHSD1more in a reductase than deydrogenase activity. This relies 
on sensitivity of the cell to the circulating insulin. Glucose uptake into tissue such as 
muscle is additionally stimulated by movement. Although the participants were 
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restricted in their movement due to the number of attachments for blood sampling, 
intravenous infusions and blood flow measurement this may falsely elevate the 
measured 11βHSD1 activity.  
With 11βHSD1 activity up to 2.5 fold higher per gram of adipose tissue in obese 
compared with lean controls (Rask et al. 2001; Rask et al. 2002) the difference in 
response to insulin between groups seen in this study may reflect the variation in 
target organ mass.   
From our in vitro data (Section 5.4) and previous in vivo work (Hughes et al. 2012), 
11βHSD1 has been shown to catalyse both the reduction of cortisone to cortisol and 
dehydrogenation of cortisol to cortisone. The generation of cortisone across adipose 
tissue and skeletal muscle in this study is thought to be the result of dehydrogenation 
by 11βHSD1. It is, however, recognised that our current D2-cortisone tracer cannot 
distinguish between the activity of 11βHSD1or 2. The localisation of 11βHSD2 in 
adipose tissue (Bujalska et al. 1999; Engeli et al. 2004; Lee et al. 2008) and skeletal 
muscle (Abdallah et al. 2005; Hassan-Smith et al. 2015; Jang et al. 2007; Whorwood 
et al. 2002) has been variable been studies. Ex vivo biopsies from this cohort would 
allow clarification of the isoenzyme responsible.  
With confirmed bidirectional activity of 11βHSD1 in vivo adverse metabolic 
phenotypes may be represent dysregulation at a cellular level of disparate reactions 
by the enzyme rather than overall enzyme activity. With a 3 to 1 ratio of reductase to 
dehydrogenase activity in subcutaneous adipose tissue the importance of this tissue 
in the development of obesity and the metabolic syndrome is reinforced (Bujalska et 
al. 1999).  In corroboration with our tissue kinetics, a similar study investigating 
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11βHSD1 across tissue in lean and obese individuals showed increased oxo-
reductase activity in adipose tissue of obese individuals  but with no difference 
across forearm skeletal muscle (Katz, et al. 1999).  
 
5.6 Conclusion 
In conclusion, in this chapter we have quantified bidirectional activity of 11βHSD1 
in vitro and in vivo using deuterated tracers and shown that obese individuals display 
predominantly 11β-reductase activity across tissue. Reductase specific inhibitors may 
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From initial recognition of the similarities between Cushing’s syndrome and the 
increasingly prevalent metabolic syndrome, to the development of 11βHSD1 
inhibitors as a novel means for the treatment of T2DM, our understanding of cortisol 
regulation and dysregulation has increased greatly over the past twenty years. The 
lack of direct relationship between circulating cortisol and measures of obesity 
implicated more complex regulation which was has been proven through 
observations of tissue specific dysregulation in both obesity and T2DM. Differing 
regulation between tissues in these two conditions provides evidence of the adaptive 
ability of 11βHSD1. Unlike in murine models whole body suppression of enzyme 
activity in humans has shown poor efficacy for the treatment T2DM and associated 
metabolic features. This thesis aims to explore the potential reasons for this by 
investigating cortisol regulation by 11βHSD1 at a cellular level.  
 
Inhibitors of 11βHSD1 have been developed for the treatment of T2DM with 
anticipated beneficial effects on cardiovascular risk factors including obesity. Few 
agents have reached phase 2 trials and their efficacy has been disappointing. If used 
commercially, such agents would likely be prescribed alongside the longstanding 
first line treatment, metformin. With the mechanism of action of metormin remaining 
uncertain, any role of metformin on 11βHSD1 activity may mask the full potential of 
these novel inhibitors.  
The effect of metfomin on 11βHSD1 activity was investigated in obese men with and 
without T2DM in a randomised placebo controlled double blinded cross over trial. 
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Through the use of the deuterated tracer D4-cortisol, whole body 11βHSD1 activity 
was increased following 28 days of metformin treatment by 10 to 15% (Ra D3-
cortisol placebo vs metformin respectively: OND; 11.2 ± 1.4 vs 12.9 ± 1.2 nmol/min 
p<0.05: ODM 14.21 ± 0.63 vs 15.78 ± 0.58 nmol/min p<0.01). This was independent 
of any glucose lowering effect by metformin as the additional control phase in the 
ODM with gliclazide treatment showed no significant effect on 11βHSD1 activity 
(Ra D3-cortisol OND: placebo 14.21 ± 0.63 vs metformin 15.78 ± 0.58 vs gliclazide 
14.21 ± 0.54 nmol/min). Obese individuals with T2DM were additionally observed 
to have increased whole body 11βHSD1 activity in comparison to the OND group 
(Ra D3-cortisol OND 11.2 ± 1.4 vs 14.21 ± 0.63 nmol/L; p<0.05). Contrary to our 
hypothesis, metformin appears to increase whole body 11βHSD1 activity suggesting 
that any reduced efficacy of 11βHSD1 inhibtiros is not through the co-administration 
of metformin.     
As a key site of splanchnic cortisol regeneration by 11βHSD1 (Andrew et al. 2005; 
Basu et al. 2009) and principle target of metformin, the liver was hypothesised as the 
likely site of any alteration in 11βHSD1 activity. Although this was not proven, it 
was suggested through the finding of a trend for upregulation of hepatic 11βHSD1 
by metformin in the ODM group. This was however a secondary outcome which the 
study was underpowered to detect. It is proposed that through improvement in insulin 
sensitivity in the liver, metformin increases cellular glucose and, through the action 
of H6PDH, increases availability of co-substrate. Measurement of insulin resistance 
using HOMA-IR showed a non-statistically significant reduction with metformin 
treatment. Previous work has shown a lack of acute effect of an alternative insulin 
sensitizing agent, namely pioglitazone in down regulating 11βHSD1 mRNA and 
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activity in adipose tissue, at least acutely. More chronic treatment over 12 weeks did 
downregulate 11βHSD1 mRNA (Wake, et al. 2007). Direct measurement of enzyme 
activity across liver is hindered by feasibility of access to hepatic blood supply. The 
use of hepatocytes in vitro would allow measurement of 11βHSD1 activity in the 
presence or absence of metformin and identification of a potential causative pathway.  
Due to its significant contribution to circulating cortisol concentrations, the most 
likely alternative causative tissue would be adipose. It would therefore be of interest 
to explore the direct effect of metformin on adipocyte 11βHSD1 either directly using 
arterio-venous sampling across the tissue or using ex vivo samples from subjects 
following administration of metformin.  
 
Isotopic tracers have allowed whole body and tissue specific measurement of 
11βHSD1 activity. Calculation of enzyme kinetics relies on plasma sampling and 
measurement of dilution of one isotope with another. Only unbound or ‘free’ 
glucocorticoids can pass across the cell membrane into the cytosol to be metabolised 
by 11βHSD1. Glucocorticoids are actively exported out of the cell back into the 
circulation with only around 5% remaining unbound within the circulating plasma 
pool. The remainder binds to carrier proteins such as CBG and albumin. Clinical 
studies to date have relied on measurement of total plasma glucocorticoids i.e. free 
plus bound for measurement of 11βHSD1 activity. This assumes equal enrichment in 
both the free and bound circulating pools with rapid turnover between the two. If this 
does not hold true then quantification of whole body 11βHSD1 activity to date may 
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have been underestimated and therefore have implications on the perceived 
contribution of tissues on whole body enzyme activity.  
With no ‘gold standard’ method available an assay was developed for isolation of 
unbound cortisol. Plasma samples from a clinical study previously performed within 
the department investigating the effect of isocaloric high carbohydrate, high protein 
and placebo meal on 11βHSD1 activity were used to compare the enrichment of D4-
cortisol by both cortisol and D3-cortisol between the free and total pools. At pre 
steady state and steady state infusion of D4-cortisol the rate of appearance of 
endogenous and D3-cortisol was reflected similarly in the free and total plasma pool. 
The effect of acute perturbation of this equilibrium was assessed using samples taken 
following administration of the isocaloric meal. Again the rate of appearance of both 
glucocorticoids was reflected similarly in the free and total pool. It is therefore 
evident that at a whole body level glucocorticoids turnover rapidly between the free 
and total pool. Through alterations in binding affinity this may not hold true in the 
presence of chronic inflammation such as with obesity or at sites of local infection 
and injury. Further investigation of the rate of turnover between the two pools across 
individual tissues and comparing lean, obese euglycaemic and obese individuals with 
T2DM may provide further insight into the patho-physiological basis underlying 
these conditions.  
 
Until recently, 11βHSD1 has been regarded principally as a reductase enzyme in 
vivo. This has been disproven through the use of a deuterated cortisone tracer and 
identification of dehydrogenase activity in both adipose tissue and skeletal muscle 
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(Hughes et al. 2012). The contribution of this activity to overall whole body 
glucocorticoid metabolism and the effect of metabolic disturbance with obesity 
remained unknown. The ability for 11βHSD1 to act as a dehydrogenase as well as a 
reductase enzyme was confirmed in vitro using HEK 293-11βHSD1 cells. A random-
order two-phase crossover single-blinded study was subsequently designed to 
investigate 11βHSD1 directionality in lean and obese healthy male volunteers.   
During steady state tracer infusion, we observed no significant difference in whole 
body rate of appearance of cortisol, D3-cortisol or cortisone between lean and obese 
individuals. Across tissue, oxo-reductase activity was statistically different from zero 
across adipose tissue in obese individuals and across skeletal muscle in lean 
individuals. By taking the ratio of reductase to dehydrogenase activity across tissue it 
was evident that 11βHSD1 acts as a predominatly reductase enzyme in adipose tissue 
and skeletal muscle in obese individuals but as a predominantly dehydrogenase 
enzyme in these tissues in lean individuals. Enzyme activity was subsequently 
perturbed using a hyperinsulinaemic-euglycamic clamp. During this phase, lean 
individuals showed an increase in oxo-reductase activity by 11βHSD1 in whole body 
and across tissue obese individuals tended to have increased cortisol generation. This 
suggests that inhibitors specifically targeting reductase activity by 11βHSD1 may 
prove more efficacious for the treatment of obesity related disorders such as T2DM. 
In this study we have confirmed bidirectional activity of 11βHSD1 in vivo and 
shown that in the setting of obesity 11βHSD1 in tissue acts as a predominantly 
reductase enzyme. With the finding of balanced reductase and dehydrogeanse 
activity in whole body with obesity, it is possible that this increase in reductase 
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activity is counterbalanced by net deyhdrogenase activity in alternative tissues such 
as liver. Further studies are needed to investigate this. With our findings in Chapter 3 
of increased whole body reductase activity in individuals with T2DM supported by 
previous published data (Stimson et al. 2011), it would also be of interest to 
investigate whether 11βHSD1 activity is predominatly dehydrogenase in OND 
individuals yet reductase in ODM individuals.   
 
To conclude, this thesis has detailed factors influencing cortisol regulation at an 
intracellular level and discussed the impact of this at whole body level in relation to 
the metabolic syndrome and T2DM.The development of novel pharmaceutical agents 
for the treatment of obesity and T2DM has been explored elucidating potential 
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